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ABSTRACT
Combination antiretroviral therapy (cART) has been hugely successful in reducing the
mortality associated with human immunodeficiency virus (HIV) infection, resulting in a
growing population of people living with HIV (PLWH). Since PLWH now have a longer life
expectancy, chronic comorbidities have become the focus of the clinical management of HIV.
For example, cardiovascular complications are now one of the most prevalent causes of death
in PLWH. Nucleoside reverse transcriptase inhibitors (NRTIs) are the backbone of cART, and
two NRTIs are typically used in combination with one drug from another drug class, such as
a non-NRTI, a protease inhibitor or an integrase inhibitor.
NRTIs were shown to induce mitochondrial dysfunction, contributing to toxicity in
numerous tissues. In rodents, short-term NRTI treatment induced an endothelial dysfunction
with an increased reactive oxygen species (ROS) production that was partially rescued by
overexpression of the mitochondrial antioxidant enzyme manganese superoxide dismutase
(MnSOD). These findings suggest that a mitochondrial oxidative stress is involved in the
pathogenesis of NRTI-induced endothelial dysfunction. We found that chronic treatment of
HAEC with 3 different representative NRTIs decreased cell replication capacity, while
increasing mtROS production and senescent cell accumulation. Furthermore, ATP-linked
respiration was reduced after chronic NRTIs treatment. Interestingly, all of these findings
were reversed by co-treating cells with NRTIs plus Q10. Thus, mitochondrial antioxidants
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may be a potential adjunct therapy for HIV patients.
Mitochondrial dysfunction, defined by a compromised mitochondrial quality control via
biogenesis and mitophagy, has a causal role in premature endothelial senescence and can
potentially initiate early cardiovascular disease (CVD) development in PLWH. In this
dissertation, we test the hypothesis that long-term NRTI treatment induces vascular
dysfunction by interfering with endothelial mitochondrial homeostasis and provoking
mitochondrial genomic instability, resulting in premature endothelial senescence.
We utilized HAEC and HIV transgenic mice to examine the causality between
mitochondrial dysfunction and endothelial senescence after chronic FTC and TDF treatment.
In HAEC, chronic NRTIs increased the expression of senescence markers and reduced
mtDNA copy number. Furthermore, the activity of Parkin-mediated mitophagy was
diminished after chronic FTC-TDF treatment. In Tg26 mice, plasma nitrite levels were
decreased, and the endothelium-dependent vasodilation of the thoracic aortas was impaired
after FTC-TDF chronic treatment. Our work suggests that long-term use of NRTI disrupts
mitochondrial homeostasis, induces premature endothelial senescence, and impairs vascular
function.
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CHAPTER 1
LITERATURE REVIEW
ENDOTHELIAL MITOCHONDRIAL SENESCENCE ACCELERATES
CARDIOVASCULAR DISEASE IN CART-RECEIVING HIV PATIENTS
1.1. Introduction
Human immunodeficiency viral (HIV) infection has been a worldwide epidemic since
the 1980s. According to the World Health Organization (WHO), in 2017, 36.9 million people
were living with HIV (PLWH), and 59% of PLWH were receiving antiretroviral treatment
(WHO, 2017). In addition, AVERT statistics indicate that HIV/AIDS-associated deaths
(940,000) had been reduced by more than 51% compared to their peak level in 2004 (1.9
million) (AVERT, 2017). The introduction of combination antiretroviral therapy (cART) has
successfully increased the life-expectancy of HIV-infected patients and propelled HIV
management into a new era (Vitoria, Rangaraj, Ford, & Doherty, 2019). HIV infection has
transformed from a fatal disease into a chronic condition, with the PLWH population stably
increasing and aging. Thus, the management of HIV-associated complications is focused not
just on opportunistic infections, but also on non-communicable, chronic diseases (Currier &
Havlir, 2017), such as cardiovascular diseases (CVD) (Hanna et al., 2016), metabolic
syndrome (Paula, Falcao, & Pacheco, 2013), renal and bone diseases (Unsal et al., 2017),
cancer (Shiels & Engels, 2017), and neurocognitive impairment (Watkins & Treisman, 2015).
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1.1.1. HIV-associated cardiovascular risks and premature aging
Several cohort studies have identified CVD as one of the most prominent causes of
morbidity and mortality among PLWH in the cART era (Croxford et al., 2017; J. Gallant,
Hsue, Shreay, & Meyer, 2017). Patients with prevalent HIV infection have a higher risk for
acute myocardial infarction than HIV negative controls, even in the absence of traditional
CVD risk factors (Freiberg et al., 2013; Paisible et al., 2015). HIV patients were reported to
have a significantly greater vascular intima-media thickness, an indicator of plaque
progression, compared to control subjects (Hsue et al., 2004). Both HIV infection and
antiretroviral treatment have been proposed as independent risk factors for early carotid
atherosclerosis (Lorenz et al., 2008). Further evidence has indicated a correlation between
antiretroviral therapy and accelerated athero-progression (Di Biagio, Del Bono, Rosso, &
Viscoli, 2012). Therefore, prevention of CVD progression has become an important
consideration in prescribing cART or making modifications in HIV therapy (Ballocca et al.,
2016).
In a cross-sectional comparison study, HIV infection increased the risk of age-associated
comorbidities even after adjustment for traditional cardiovascular risk factors such as
smoking, diet, etc (Schouten et al., 2014). Another noticeable finding from this and other
cohort studies was that age-associated comorbidity occurred earlier in younger PLWH and
exhibited a higher incidence rate compared to the same age group within a non-HIV-infected
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population (Davies, Gompels, Johnston, Bovill, & May, 2013; Guaraldi et al., 2011).
Moreover, long-term exposure to cART is proposed to predispose and potentiate the early
onset of CVD (Guaraldi et al., 2010). Both HIV infection and antiretroviral treatment are
reported risk factors for age-associated comorbidities in older PLWH (Onen et al., 2010).
These observations led to the hypothesis that PLWH receiving cART exhibit premature and
accelerated aging. Immuno-senescence is characterized by continuous, systemic, low-grade
inflammation that is proposed to predispose age-associated comorbidities in HIV patients
(Molina-Pinelo et al., 2009). However, cART was shown to successfully replenish CD4+ cell
counts and decrease systemic viral load (Kahn et al., 2011; Palumbo et al., 1998). Therefore,
the data support that cART is a risk factor for premature aging that is at least in part
independent of HIV infection status.
1.1.2. Nucleoside reverse transcriptase inhibitors induce endothelial dysfunction
The first nucleoside reverse transcriptase inhibitor (NRTI), zidovudine (AZT), was
approved and available for use as a monotherapy to treat HIV infection in 1987 (Fischl et al.,
1987). Several NRTIs and other classes of drugs, including the protease inhibitors (PI),
integrase inhibitors (II) and nonnucleoside reverse transcriptase inhibitors (NNRTI), were
approved and released onto the market in the following three decades. New classes of drugs
like the entry and the integrase inhibitors and their co-formulation with NRTIs are also in
development. NRTIs are used in combination with one or two antiretroviral drugs from other
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classes in cART. In the late 1990’s, the use of 2 NRTIs together with a PI significantly
improved immune function and reduced viral load in HIV patients (J. E. Gallant et al., 2006).
There are now over 20 different FDA-approved combinations used in HIV therapies, and the
fixed-dose co-formulation of two NRTIs, emtricitabine (FTC) and tenofovir disoproxil
fumarate (TDF), is now widely used in cART since 2004 (AIDSinfo, 2019; Pozniak et al.,
2006). Temporarily discontinuing cART can cause viral rebound and may even promote drug
resistance; therefore, strict adherence to long-term cART is necessary. Since HIV patients
now have a longer life expectancy, the presentation of chronic cART toxicity is likely
inevitable. Individual NRTIs exhibit differing toxicity profiles across numerous tissues. Early
on, neurological adverse effects and mitochondrial myopathies were described in patients
receiving AZT (Dalakas et al., 1990; Rachlis & Fanning, 1993). Stavudine (d4T), didanosine
(ddI), and zalcitabine (ddC) induced peripheral neuropathy was also associated with
mitochondrial toxicities (Cui, Locatelli, Xie, & Sommadossi, 1997; Simpson & Tagliati,
1995). An induction of a leukocyte and endothelial cell interaction resulting in vascular
damage was reported in abacavir (ABC) and ddI-treated patients (De Pablo et al., 2010). In
rodent studies, AZT was reported to promote vascular wall remodeling via an oxidantdependent pathway (Jiang et al., 2010). NRTI-induced endothelial dysfunction was reported
in numerous rodent studies, and in PLWH, NRTIs were shown to predispose patients to
atherosclerosis or coronary heart disease (Group et al., 2008; Jiang, Hebert, Zavecz, &
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Dugas, 2006; Msoka et al., 2018). Most studies suggest that mitochondrial dysfunction
underlies NRTI-induced endothelial dysfunction. However, the mechanism is not well
delineated yet. To examine hypotheses for how and whether these mitochondrial toxicities
initiate the premature CVD observed in PLWH, in the next section, we will review the role of
endothelia and endothelial mitochondria in vascular function and homeostasis.
1.2. Endothelial cells play an important role in vascular homeostasis
The endothelium is indispensable in mediating vascular homeostasis, including its
regulation of vessel integrity, immune cell adhesion, angiogenesis, and vascular permeability.
It also serves important paracrine, endocrine and autocrine functions by releasing factors,
such as nitric oxide (NO), prostacyclin (PGI2), endothelin-1 (ET-1), and vascular endothelial
growth factor (VEGF) (Inagami, Naruse, & Hoover, 1995; H. C. Lee & Wei, 2012; Sato &
Murota, 1995) that regulate vascular smooth muscle cells, platelets and inflammatory cells.
These and other endothelium-derived factors are essential for regulating vascular tone, blood
flow, inflammatory responses, and blood fluidity (Feletou, 2011). Regulating the balance
between vasoconstriction and vasodilation is one of the major functions of vascular
homeostasis, and NO is a crucial mediator in this regulation. In response to acetylcholine,
bradykinin, serotonin, or shear stress, endothelial nitric oxide synthase (eNOS) utilizes Larginine to generate NO (Benedito, Prieto, Nielsen, & Nyborg, 1991; Janssens, Shimouchi,
Quertermous, Bloch, & Bloch, 1992; Palmer, Ashton, & Moncada, 1988; Pollock et al.,
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1991). Endothelium-derived NO is a vasodilator that diffuses into vascular smooth muscle
cells (VSMC) and activates a cGMP signaling pathway, subsequently leading to VSMC
relaxation (Archer et al., 1994; Joannides et al., 1995). Additionally, NO has an antiatherogenic effect mediated through its prevention of VSMC proliferation, platelet
aggregation, and leukocyte adhesion (Emerson et al., 1999; Kubes, Suzuki, & Granger, 1991;
Momi et al., 2012; Sarkar, Meinberg, Stanley, Gordon, & Webb, 1996). Endothelial
dysfunction is associated with reduced eNOS expression or decreased synthesis, release, or
activity of NO. NO is a known inhibitor of the electron transport chain (ETC) that competes
with oxygen at complex IV to induce reactive oxygen species (ROS) production (Cassina &
Radi, 1996; Sarti et al., 2003). Long-term exposure to NO causes continuous inhibition of
complex I through an S-nitrosylation that is potentially pathogenic (Clementi, Brown,
Feelisch, & Moncada, 1998). Thus, it is important to investigate the role of mitochondria in
endothelial pathobiology.
1.3. Endothelial mitochondria
Endothelial cells are a highly glycolytic cell type that depends on glycolysis for more
than 75% of their ATP production (Culic, Gruwel, & Schrader, 1997). In cultures of coronary
endothelial cells, at physiological concentrations, 99% of glucose is catabolized into lactate
for glycolytic energy supply (Krutzfeldt, Spahr, Mertens, Siegmund, & Piper, 1990).
Additionally, mitochondrial content in endothelial cells is relatively low, at around 6-13% of
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the cell volume across various species, compared to myocytes that are approximately 30% by
volume (Barth, Stammler, Speiser, & Schaper, 1992; Oldendorf, Cornford, & Brown, 1977).
Thus, their low mitochondrial content might suggest that oxidative phosphorylation in
endothelial cells is not designed for energy supply. Instead, numerous studies suggest that in
vascular endothelial cells, mitochondria are more likely functioning as signaling organelles,
mediating cell fate decisions, such as angiogenesis, apoptosis, or senescence, (Y. M. Kim et
al., 2018; Marcu et al., 2015; Quintero, Colombo, Godfrey, & Moncada, 2006;
Ramachandran et al., 2002). Mitochondria are known to be major contributors of cellular
ROS, and complexes I and III along the ETC are the major ROS sources from mitochondria
(Chen, Vazquez, Moghaddas, Hoppel, & Lesnefsky, 2003; Kushnareva, Murphy, & Andreyev,
2002). Mitochondrial ROS (mtROS) play an essential role in cell signaling, and its
production is regulated through interdependent changes in mitochondrial membrane potential,
dismutase and peroxidase enzymes, NO, and calcium flux (Brookes, Yoon, Robotham,
Anders, & Sheu, 2004; Turrens, 2003). The structure and cellular distribution of mitochondria
are important for communicating with other organelles, especially the endoplasmic reticulum
(ER) and nucleus. Mitochondria are considered sensors in calcium signaling and together
with the ER, buffer calcium flux to maintain cellular calcium homeostasis (Lawrie, Rizzuto,
Pozzan, & Simpson, 1996; Rizzuto, De Stefani, Raffaello, & Mammucari, 2012; Rizzuto et
al., 1998). Even though mitochondria are not the main powerhouse in endothelial cells, they
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contribute significantly to maintaining cellular function.
1.3.1. Mitochondria buffer calcium flux and mediate calcium signaling
Mitochondria are the second largest calcium storage site in the cell, serving as an
important calcium buffering system in maintaining calcium homeostasis (David, Barrett, &
Barrett, 1998; Hacker & Medler, 2008; Werth & Thayer, 1994). Mitochondrial calcium load
is crucial for signal transduction, cell survival, and cell metabolism; therefore, the uptake and
release of calcium in mitochondria are highly regulated by specific ion channels (Gilabert &
Parekh, 2000; Hoth, Button, & Lewis, 2000). Uncoupling proteins 2 and 3 (UCP2 and UCP3)
are fundamental for mitochondrial calcium sequestration and possess mitochondrial calcium
uniporter (MCU) activity (Trenker, Malli, Fertschai, Levak-Frank, & Graier, 2007; WaldeckWeiermair et al., 2010). Moreover, UCP2 is the primary isoform in endothelial cells. In
human umbilical vein endothelial cells (HUVEC), AMP-activated protein kinase (AMPK)
upregulates UCP2 to attenuate oxidative stress in high glucose conditions (Xie, Zhang, Wu,
Viollet, & Zou, 2008). The cAMP/ protein kinase A (PKA) pathway can also activate UCP2
transcription and modulate the mitochondrial level of calcium. In a mouse model, loss of
function in PKA-UCP2 regulation led to mitochondrial dysfunction and excessive ROS,
resulting in endothelial dysfunction in coronary arterioles (Xiong et al., 2016). Other than
buffering calcium fluctuations, alterations in mitochondrial calcium also contribute to
endothelial cell responses to stimuli. In endothelial cells, calcium flux between mitochondria
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and the ER is reportedly a critical component of endothelial responses to fluid shear stressinduced calcium transients and oscillations. This association highlights a mechanism whereby
endothelial mitochondria regulate mechano-transduction (Scheitlin et al., 2016). Additionally,
a recent study shows that shear stress activates mitochondrial ATP generation and triggers
purinergic calcium signaling in endothelial cells (Yamamoto, Imamura, & Ando, 2018).
Endothelial mitochondrial depolarization activates eNOS by increasing intracellular calcium
concentration and phosphoinositide-3 kinase (PI3K)-induced eNOS phosphorylation to
promote cerebral artery vasodilation (Katakam et al., 2013). Thus, mitochondria function not
only as a calcium buffer but also tightly mediate endothelial function via calcium signaling.
1.3.2. Mitochondrial ROS serve as cell signaling molecules
mtROS act as important signaling molecules that initiate cellular responses to
endogenous stresses and exogenous stimuli in the vascular endothelium. In response to
certain stimuli, excessive production of mtROS activates downstream nuclear factor-κB (NFκB) and protein kinase C (PKC) in endothelial cells, promoting pro-inflammatory and prothrombotic pathways (Pueyo et al., 2000; Ungvari et al., 2007). Despite excessive oxidative
stress, mtROS is proposed as a signaling mediator for endothelial cell activation in early
atherogenesis (Y. Wang & Tabas, 2014). mtROS are also reportedly responsible for
vasodilation in response to shear stress in human coronary arteries (Liu et al., 2003).
Oscillatory shear stress (OSS) exposed arterial regions are considered lesion-prone sites in
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atherosclerosis. Chronic exposure to OSS stimulates superoxide production via nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase and JNK activation to promote vascular
oxidative stress and increase the risk of atherosclerosis (Hwang et al., 2003; Takabe et al.,
2011). By regulating the nuclear binding of activator protein-1 and inducing intercellular
adhesion molecule-1 gene expression, mtROS contribute to lysophosphatidylcholine-induced
endothelial activation in primary human aortic endothelial cells (Li et al., 2016). Additionally,
mtROS contribute to endothelial dysfunction through eNOS uncoupling and are likely also
involved in the ensuing vascular disease. NADPH oxidase 4 (Nox4) mediates a peroxynitritedependent uncoupling of eNOS in response to angiotensin II (D. Y. Lee et al., 2013). Other
than pathogenic conditions, mtROS also engage p38α and the motor adaptor complex, Miro
(an outer mitochondrial membrane protein)/Trak (trafficking kinesin proteins), to control
mitochondrial motility (Debattisti, Gerencser, Saotome, Das, & Hajnoczky, 2017). Thus,
mtROS mediated cell signaling plays a critical role in both physiological function and
pathogenic conditions.
1.3.3. Mitochondria mediate endothelial cell fate decisions
Mitochondria regulate endothelial cell fate, including senescence, necrosis, and
apoptosis, in response to intrinsic and extrinsic stimuli. Intrinsic apoptosis is induced by
several cellular stressors, such as ROS, hypoxia, or DNA damage (Circu & Aw, 2010;
Stempien-Otero et al., 1999). Intrinsic stimuli activate pro-apoptotic factors, BCL2-

10

associated X protein (BAX) and BAK, to induce permeabilization and depolarization of the
mitochondrial outer membrane, resulting in cytochrome c leakage (Finucane, Bossy-Wetzel,
Waterhouse, Cotter, & Green, 1999; Oltvai, Milliman, & Korsmeyer, 1993). Mitochondrial
fission and fusion dynamics were shown associated with the induction of outer mitochondrial
membrane (OMM) permeabilization and apoptosis (Brooks et al., 2007; Suen, Norris, &
Youle, 2008). Extrinsic apoptotic stimuli such as the hyperglycemia occurring in diabetic
conditions have been reported in many studies (Favaro et al., 2008; Ido, Carling, &
Ruderman, 2002). High glucose increases ROS through a PI3K/Akt-dependent pathway and
induces NF-κB, upregulating cyclooxygenase 2 (COX2) and triggering an induction in
caspase-3 activity, resulting in endothelial apoptosis (Sheu et al., 2005). The activation of
AMPKα by C-peptide prevents hyperglycemia-induced ROS generation, ROS-mediated
mitochondrial fission, and endothelial apoptosis, thus protecting against diabetic
vasculopathy (Bhatt, Lim, Kim, & Ha, 2013). Mitochondria are also known involved in the
induction of necrosis through mitochondrial phosphoglycerate mutase-5/protein phosphatase
(PGAM5) (Z. Wang, Jiang, Chen, Du, & Wang, 2012). For example, nitration of the
mitochondrial complex I subunit NDUFB8 was shown to contribute to endothelial necrosis
(Davis et al., 2010). Mitochondria function in endothelial necrosis is not yet well delineated,
but the physiologic and pathogenic associations between mitochondrial dynamics and
endothelial necrosis is a direction of current research.
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Mitochondria-derived intrinsic stress is an effective inducer of senescence, with factors
such as mtROS, mitochondrial dynamics, bioenergetics, metabolic state, mitochondrial DNA
(mtDNA) integrity, and calcium homeostasis, broadly discussed in this context (Lauri,
Pompilio, & Capogrossi, 2014; Ziegler, Wiley, & Velarde, 2015). Endothelial senescence is
reportedly associated with an impairment of mitochondrial biogenesis, reduced mitochondrial
mass, and an altered expression profile for its component mitochondrial proteins (Dai,
Rabinovitch, & Ungvari, 2012). A downregulation in cytochrome c oxidase (ETC complex
IV) and its catalytic activity has been reported in senescent endothelial cells (Xin, Zhang,
Block, & Patel, 2003; Zhang, Block, & Patel, 2002). In addition, deficiency in the
mitochondrial antioxidant manganese superoxide dismutase (MnSOD) increases endothelial
dysfunction (Ohashi, Runge, Faraci, & Heistad, 2006). In replicative senescence, there is an
increment in mitochondrial superoxide production, suggesting an MnSOD dysregulation in
endothelial senescence. In MnSOD haplo-insufficient mice (SOD+/-), an increase in
mitochondrial oxidative stress causes an age-related decline in mitochondrial function,
resulting in endothelial dysfunction (Brown, Didion, Andresen, & Faraci, 2007; Kokoszka,
Coskun, Esposito, & Wallace, 2001). Finally, morphological changes in mitochondria have
been reported in studies of senescence (Yoon et al., 2006), and decreases in both fusion and
fission activities in senescent HUVEC mitochondria suggests dysregulation of mitochondrial
dynamics, contributing to an accumulation of damaged mitochondria during aging (Jendrach

12

et al., 2005). Thus, endothelial senescence is tightly linked with mitochondrial function. An
alteration in mitochondrial quality control, such as fission and fusion, mitochondrial
biogenesis, or mitophagy, and its association with senescence will be discussed in detail in a
later section.
1.4. NRTIs induce endothelial dysfunction and endothelial senescence
The pathogenesis of CVD in PLWH is complex, involving systemic viral proteininduced damage, chronic inflammation, adverse effects of cART, and traditional risk factors
all serving as contributing factors promoting chronic CVD comorbidity. The use of cART is
associated with dyslipidemia, lipodystrophy, and insulin resistance in HIV patients, and these
metabolic conditions are associated with atherosclerotic risk in CVD (C. T. Lambert et al.,
2016). NRTI is the main backbone of cART. Thus, surveillance of their long-term pathogenic
influence on CVD is essential and may aid in identifying medication options for an improved
quality of life for patients. Endothelial dysfunction is an initiating event in atherogenesis and
its subsequent CVD; thus, the contribution of NRTI treatment in promoting endothelial
dysfunction is an important area of study. The first NRTI, the thymidine analogue AZT, was
shown to induce increased levels of superoxide and reduced endothelium-dependent
vasorelaxation in the aortas of mice treated for 35 days (Sutliff et al., 2002). Combination
treatment of mice with AZT plus indinavir, a protease inhibitor, impaired endothelial function
via an oxidant-dependent pathway, and their long-term administration promoted vascular
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remodeling (Jiang et al., 2010). In a cohort study, HIV patients receiving ABC, a guanosine
analog, exhibited lower flow-mediated vasodilation (FMD) of the brachial artery than those
not on ABC, suggesting that ABC treatment impairs endothelial function (Hsue et al., 2009).
In in vitro studies, ABC also increased platelet reactivity via inhibition of soluble guanylyl
cyclase, resulting in enhanced platelet adhesion (Baum, Sullam, Stoddart, & McCune, 2011).
This finding suggests an increased risk of vascular damage and possibly, CVD development.
According to WHO guidelines for the use of antiretroviral drugs for treating HIV
infection, the fixed-dose combination of TDF, FTC (or lamivudine, 3TC) and efavirenz (EFZ,
an NNRTI) is the preferred first-line cART for adults and adolescents. In 2018, the guidelines
were updated to include the integrase inhibitors dolutegravir (DTC) and raltegravir (RAL) as
first-line regimens; however, the fixed-dose TDF-FTC (or 3TC)-EFZ regimen is still the most
preferred cART for HIV post-exposure prophylaxis (WHO, 2018). To date, the TDF/ FTC
combination has not been linked with prominent vascular damage. In fact, in a flow chamber
model using HUVEC and peripheral blood mononuclear cells (PBMC), TDF and FTC
combination treatment did not significantly affect PBMC rolling and adhesion and exhibited
a better vascular profile than the ABC and 3TC co-treated group (De Pablo et al., 2012).
However, in this study, the cells were treated with NRTIs for only 4 hours; therefore, it is not
yet known whether chronic treatment with these NRTI will alter endothelial function.
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The excess production of mitochondria-derived ROS has been proposed as the main
cause of NRTI-induced endothelial dysfunction (Jiang et al., 2007). Endothelial dysfunction
resulting from an acute or “short-term exposure” to NRTI was shown rescued by
mitochondrial antioxidant MnSOD overexpression (Glover et al., 2014). However, chronic,
excessive production of ROS may overwhelm endogenous antioxidant capacity, inducing a
sustained endothelial dysfunction that gives rise to superoxide production rather than NO, a
phenomenon termed eNOS uncoupling. The resulting vicious cycle of ROS production may
presumably cause stress-induced premature senescence in endothelial cells. eNOS uncoupling
is considered a hallmark event in aged vessels (Yang, Huang, Kaley, & Sun, 2009). In
endothelial cells, NOX4, one of the main superoxide-generating enzymes, was found
associated with the ER stress signaling that contributes to eNOS uncoupling and the aging
process (H. Y. Lee, Zeeshan, Kim, & Chae, 2017). Prematurely senescent endothelial cells
exhibit an impaired eNOS-NO system and an increased peroxynitrite formation that fits with
known characteristics of vascular aging (van der Loo et al., 2000). AZT-induced
mitochondrial dysfunction and oxidative stress were proposed contributors to premature
senescence in fibroblast and adipocytes (Caron, Auclairt, Vissian, Vigouroux, & Capeau,
2008). Though the mechanism of NRTI-associated premature senescence remains unclear,
NRTI-induced mitochondrial dysfunction may be an underlying cause. Chronic NRTI studies
may help to decipher this unresolved question.
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1.5. NRTIs promote premature senescence
Cellular senescence was first proposed in primary somatic cell culture, where cells
showed an irreversible loss of replicative capacity, a phenomenon known as the “Hayflick
limit” after repetitive passaging. (Hayflick & Moorhead, 1961). Subsequent studies showed
that telomere shortening was a mechanism underlying cellular senescence (Bodnar et al.,
1998; Watson, 1972). Numerous studies described that PLWH receiving antiretroviral
treatment exhibit a premature decline in physiologic function and an early onset of agingassociated diseases, such as coronary heart disease. Among the various antiretroviral drug
classes, the NRTIs are known inducers of mitochondrial dysfunction, and mitochondria
dysfunction reportedly initiates premature cellular senescence (Johnson et al., 2001; Wiley et
al., 2016). In addition to NRTI-induced mitochondrial dysfunction, AZT and d4T disrupt
telomerase maintenance, resulting in telomere shortening and cellular senescence (Strahl &
Blackburn, 1994). Though the mechanism of NRTI-induced senescence is not yet determined,
most researchers hypothesize that mitochondrial dysfunction plays a causal role (Caron et al.,
2008). In support of this consensus, increased mitochondrial oxidative stress, disruption of
mitochondrial bioenergetics, imbalance in the mitochondrial life cycle, and accumulation of
mitochondrial DNA damage or mutations all critically contribute to cellular senescence and
aging (H. C. Lee & Wei, 2012; Wiley et al., 2016). NRTI-associated mitochondrial toxicity
and its contribution to senescence are described in the following sections.
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1.6. NRTI-associated mitochondrial toxicity promotes premature senescence
The clinical side effects of NRTI, such as myopathy, peripheral neuropathy, or
lipoatrophy, are believed to result from their mitochondrial toxicity (Dalakas et al., 1990;
Scruggs & Dirks Naylor, 2008; Shikuma et al., 2001; Simpson & Tagliati, 1995). NRTIs are
analogs of nucleosides that are phosphorylated intracellularly to form 5’-triphosphates, then
compete with the native nucleotide pool to be incorporated into pro-viral DNA during its
reverse transcriptase-driven viral replication. These structural analogs have no 3’-OH group,
so promote early termination of the viral DNA chain. In some cases, NRTIs serve as
substrates for polymerase-ɣ (pol-ɣ) to inhibit mtDNA replication. This leads to premature
termination of mtDNA replication, a reduced mtDNA content, and consequently, to decreases
in ETC activity and oxidative phosphorylation and increases in mtROS production (Lewis,
Gonzalez, Chomyn, & Papoian, 1992; Lewis et al., 2001). Long-term exposure to AZT
reportedly increases cellular and mitochondria-specific superoxide and decreased
mitochondrial membrane potential, suggesting mitochondrial dysfunction (Kline et al., 2009).
ETC dysfunction may result secondary to the interruption of mtDNA or DNA replication that
in turn enhances NRTI-associated mitochondrial toxicity. However, some of the NRTIs
inhibit mitochondrial complexes directly, independent of their impact on mtDNA depletion.
In isolated mitochondria, AZT inhibit the mitochondrial adenylate kinase and adenosine
nucleotide translocator, which increases oxidative stress and undermines oxidative
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phosphorylation capacity (Barile, Valenti, Passarella, & Quagliariello, 1997). In HepG2 cells,
AZT and ddC prevent phosphorylation of the NDUFB11 subunit of complex I, inducing
direct inhibition of complex I activity and increased superoxide production (Lund & Wallace,
2008). Other than direct inhibition of mtDNA replication by NRTI, pol-ɣ activity and mtDNA
integrity are also sensitive to NRTI-derived oxidative damage. Mitochondrial ROS signaling
is involved in many pathological and physiological processes, such as apoptosis,
bioenergetics, and the signaling of fatty acid metabolism. NRTIs alter mitochondrial
homeostasis and regulate cell fate pathways that contribute to their mitochondrial toxicity.
Inhibition of dynamin-related protein 1 (Drp-1), a mitochondrial fission-mediating protein,
reportedly attenuates ddC-induced hyperalgesia in rats (Ferrari, Chum, Bogen, Reichling, &
Levine, 2011). There is as yet no conclusive mechanism of NRTI-associated mitochondrial
toxicity. However, long-term NRTI treatment induced alterations in mitochondrial quality
control and mtDNA stability may be central contributors to NRTI-induced premature
senescence.
1.6.1. Dysregulated mitochondrial quality control facilitates senescence
Mitochondrial biogenesis, together with fission-fusion dynamics and mitophagy, are
tightly coordinated mitochondrial quality control mechanisms that maintain mitochondrial
homeostasis. Selective mitochondrial autophagy, termed mitophagy, is part of the
mitochondrial quality control mechanism that eliminates damaged mitochondria in a
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mitochondrial fission-dependent manner (Frank et al., 2012). PTEN-induced kinase 1
(PINK1), an upstream regulator of the PINK1-Parkin-mediated mitophagy pathway, is
selectively stabilized on depolarized mitochondria and through its kinase activity, activates
Parkin translocation to mitochondria (Jin et al., 2010; D. P. Narendra et al., 2010). Parkin is a
cytosolic E3 ubiquitin kinase that is selectively recruited to depolarized mitochondria to
initiate poly-ubiquitination of proteins and promote mitochondrial autophagy (D. Narendra,
Tanaka, Suen, & Youle, 2008). PINK1-Parkin-mediated mitophagy was shown to protect
endothelial cells from metabolic stress-induced damage (W. Wu et al., 2015). An inability to
maintain a healthy mitochondrial population in endothelial cells was shown increase the risk
of CVDs like diabetes mellitus, atherosclerosis, and hypertensive heart diseases (Kluge,
Fetterman, & Vita, 2013; Madamanchi & Runge, 2007; Soleimanpour et al., 2014). Also,
attenuated Parkin-mediated mitophagy was shown associated with aging- and doxorubicinmediated cardiomyopathy (Hoshino et al., 2013). In this same study, the authors found that
cytosolic p53 binds to Parkin and inhibits its translocation to mitochondria, thus inhibiting
Parkin-mediated mitophagy and promoting mitochondrial dysfunction in cardiomyocytes.
However, p53 deficiency in mice protected them against aging- and doxorubicin-mediated
functional decline in the heart and their mitochondria. Moreover, the expression of fissionmediated proteins, Drp1 and mitochondrial fission 1 protein (Fis1), are decreased in
senescent cells (Mai, Klinkenberg, Auburger, Bereiter-Hahn, & Jendrach, 2010). Inhibition of
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mitochondrial fission via Drp-1 downregulation results in elongated mitochondria,
suppressed autophagic flux, and premature senescence in endothelial cells (Lin, Shen, Yan, &
Gao, 2015). Enhanced mitochondrial quality control via upregulation of autophagy-mediating
proteins, LC3B, ATG5, and ATG12, was proposed to extend replicative lifespan in HUVEC
(Mai, Muster, Bereiter-Hahn, & Jendrach, 2012). The above findings suggest a mutual
influence between mitophagy and senescence that the dysregulation or inhibition of
mitophagy impairs cellular function and consequently leads to senescence, and that
senescence also induces an attenuation in mitophagic activity. NRTI-induced mitochondrial
toxicity may be tightly associated with the dysregulation of this quality control. In endothelial
cells, a single dose of NRTI treatment increases the autophagy marker LC3 and the
colocalization of mitochondria and autophagosome within 6 to 8 hours, suggesting NRTI
induces mitophagic activity (Xue et al., 2013). Thus, increased mitophagic activity after
NRTI treatment is protective for cells, allowing for the removal of damaged mitochondria
within a short period of time. However, chronic toxicity or excessive oxidative stress
resulting from long-term NRTI treatment may compromise protective mitophagic
mechanisms, allowing for the accumulation of damaged mitochondrial components to
promote premature senescence.
Peroxisome proliferator receptor-ɣ coactivator 1α (PGC-1α) is a master regulator of
mitochondrial biogenesis and respiration, gluconeogenesis, thermogenesis in brown adipose
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tissue, and other metabolic processes (Puigserver et al., 2003; Puigserver et al., 1998; Z. Wu
et al., 1999). In endothelial cells, PGC-1α has been reported to show anti-apoptotic, antiROS, and anti-inflammatory properties (Borniquel, Valle, Cadenas, Lamas, & Monsalve,
2006; H. J. Kim et al., 2007; Won et al., 2010). PGC-1α regulates the mitochondrial
antioxidant defense system in endothelial cells by regulating the expression of ROSdetoxifying enzymes, including MnSOD, peroxiredoxin III, and peroxiredoxin V, etc (Valle,
Alvarez-Barrientos, Arza, Lamas, & Monsalve, 2005). PGC-1α deficiency causes
downregulation of SIRT1 and the antioxidant catalase, the presentation of abnormal
mitochondria, reduced telomerase activity and increased expression of the senescence marker
p53 in mouse aorta (Xiong et al., 2013). These findings suggest that PGC-1α is a key
regulator of the mitochondrial antioxidant system and a negative regulator of vascular
senescence. Although decreased PGC-1α was reported in AZT-treated embryonic rat heart
tissues, and its overexpression protected cardiomyocytes from NRTI-induced mitochondrial
toxicity (Liu et al., 2015), whether PGC-1α in endothelial cells responds to chronic NRTIinduced damage and results in mitochondrial dysfunction or premature senescence is as yet
unclear.
1.6.2. Loss of mtDNA stability accelerates senescence
mtDNA is a circular, double-stranded DNA that is highly redundant. Depending on the
cell type, it varies from hundreds to thousands of copies per cell. MtDNA contains genes
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encoding 13 subunits of the ETC components, 2 rRNA, and 22 tRNAs, indicating that a
decrease in abundance or mutation could impair mitochondrial ETC function (Anderson et
al., 1981; Bai et al., 2004). The integrity of mtDNA is essential for maintaining cellular
function; its continuous replication and transcription are tightly coupled to sustaining
mitochondrial function. MtDNA depletion and mutation are found in aging mammalian cells,
suggesting that mtDNA integrity is an underlying factor in the progression of aging (Bua et
al., 2006; Cree et al., 2008; Herbst et al., 2016). Mitochondria are the major site for cellular
ROS generation, and its excessive production results in impaired mitochondrial activity and
mtDNA damage to exacerbate cellular aging. ROS production at ETC complex I is inversely
correlated with a maximum life span in vertebrates (A. J. Lambert et al., 2007). Also,
complex I-derived ROS are thought to be a main reason for oxidative damage to DNA.
Without proper repair, this oxidative damage would be propagated and fixed in mtDNA,
eventually resulting in mtDNA mutations. It has been described in mutator transgenic mice
that a large amount of mtDNA deletion and mutation are driving forces for premature aging
(Kujoth et al., 2005; Trifunovic et al., 2004; Vermulst et al., 2008). Therefore, the level of
mtDNA mutation and mtDNA copy number could be indicators for mtDNA integrity and
aging progression.
It’s is widely known that telomere shortening triggers p53-dependent DNA damage, and
activated p53 results in cell cycle arrest, senescence, and apoptosis (Milyavsky et al., 2001;
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Saretzki, Sitte, Merkel, Wurm, & von Zglinicki, 1999). Interestingly, upon telomere
dysfunction, activated p53 directly represses the expression of PGC-1α, PGC-1β, and their
downstream genes, suggesting that telomere dysfunction may suppress mitochondrial
biogenesis (Sahin et al., 2011). This fact also implies that compromised mitochondrial
function may be involved in the outcome of p53 activation, i.e.., cell cycle arrest, senescence,
and apoptosis. Moreover, ablation of PGC-1α reduces the expression and activity of
telomerase reverse transcriptase (TERT), indicating a negative feedback mechanism between
PGC-1α downregulation and telomere dysfunction (Xiong, Patrushev, Forouzandeh, Hilenski,
& Alexander, 2015). TERT was shown imported into mitochondria by targeting its Nterminus to mitochondria, where it sensitizes cells to hydrogen peroxide-induced mtDNA
damage (Santos, Meyer, Skorvaga, Annab, & Van Houten, 2004). On the other hand,
mitochondrial TERT was found to increase mitochondrial membrane potential and respiratory
chain activity, reduce ROS production and protect mtDNA against damage (Haendeler et al.,
2009). In the same study, the mitochondrial TERT was shown to bind to ND1 and ND2
genes. Therefore, the authors hypothesized that mitochondrial TERT increases the synthesis
of complex I subunits to counteract ROS production. However, mechanisms regulating TERT
transport into mitochondria and its protection of the mitochondrial genome are not clear and
will required additional investigation.
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Defective mtDNA replication, mtDNA depletion, and altered mitochondrial
ultrastructure have been reported for NRTI treatment (Lewis et al., 1992; Lewis et al., 1991).
In addition, NRTIs have been shown to promote mtROS production, and excess oxidative
stress induces mtDNA damage and its degradation (Shokolenko, Venediktova, Bochkareva,
Wilson, & Alexeyev, 2009). ROS is a major cause of mtDNA damage, and it has been
proposed that oxidative damage to mtDNA is inversely related to maximum life span in
mammals (Barja & Herrero, 2000). Senescence, defined as a permanent arrest in
proliferation, can result from p53 activation (Herbig, Jobling, Chen, Chen, & Sedivy, 2004).
The p53-p21 signaling axis is a widely known pathway for replicative senescence; p21 is
transcriptionally up-regulated by p53, and then triggers G1-phase cell cycle arrest by
inhibiting Cdk2 and Cdk4 (Ben-Porath & Weinberg, 2005). The overexpression of p53 in
mitochondria increases the sensitivity of mammalian cells to NRTI, ddC or ddI exposure,
reducing their mtDNA abundance and mitochondrial respiratory capacity (Koczor et al.,
2012). In summary, the above findings suggest that chronic NRTI treatment may facilitate
mitochondrial genomic instability, provoking endothelial dysfunction and premature
endothelial senescence, in turn contributing to atherosclerosis progression.
1.7. Hypothesis and aims
NRTI induced mitochondrial dysfunction and oxidative stress contributes to premature
cellular senescence in human fibroblasts (Caron et al., 2008). Mitochondrial dysfunction,
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including a compromised mitochondrial quality control, has a causal role in endothelial
senescence that can exacerbate CVD development. Endothelial senescence is an early event
in atherosclerosis and decreased PGC-1α expression has been demonstrated in human
atherosclerosis (McCarthy et al., 2013). Additionally, NRTI may potentially decrease PGC-1α
expression and its downregulation may in turn downregulate mitochondrial biogenesis and
TERT expression and activity. These alterations would theoretically compromise
mitochondrial function and promote cellular senescence. Therefore, we hypothesized that
long-term use of NRTI induces endothelial dysfunction by disturbing mitochondrial
homeostasis and provoking mitochondrial genomic instability, resulting in premature
endothelial senescence.
1.7.1. Aim 1: Determine whether chronic exposure to NRTI results in premature
endothelial senescence and whether it could be rescued by coenzyme Q10
Chronic NRTI treatment has direct effects on the ETC and exposes endothelial cells to a
sustained high level of ROS. The working hypothesis is that NRTI-induced mtROS exhausts
the mitochondrial antioxidant system, promoting a vicious cycle of ROS production and
subsequently, endothelial cell senescence. We measured the ROS levels and endothelial
senescent markers in cultured endothelial cells treated with NRTI±Q10 chronically.
1.7.2. Aim 2: Examine whether chronic exposure to NRTI compromises mitophagy and
further interferes with the mitochondrial function
Mitochondrial damage accumulates over a regular cell lifespan. Fission is the
mechanism that separates damaged mitochondrial components for elimination through
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autophagy, specifically called “mitophagy” for mitochondrial cargo. The working hypothesis
is that chronic NRTI treatment prompts impairing mitophagy and unbalancing mitochondrial
homeostasis in endothelial cells. Different mitophagy pathways were evaluated in cultured
endothelial cells after continuous incubating in NRTI. Mitochondrial respiration was recorded
by utilizing oxygraphy.
1.7.3. Aim 3: Investigate whether chronic NRTI exposure promotes endothelial
senescence by eliciting instability of the mitochondrial genome
mtDNA is relatively vulnerable since there is no histone wrapping, and mitochondria
lack efficient DNA repair mechanisms. The elevated level of ROS causes oxidative damage
in mtDNA that would result in mtDNA degradation or mutation if not repaired. The working
hypothesis is that NRTI-induced sustained ROS produces mtDNA damage that leads to
mitochondrial dysfunction and premature cellular senescence. mtDNA copy number were
detected by quantitative PCR.
1.7.4. Aim 4: Evaluate the vascular endothelial function after chronic NRTI treatment in
vivo
We treated Tg26 mice that express a transgene containing modified HIV-1, with NRTI
for 12-14 weeks. Endothelial dysfunction is the hallmark of CVD, thus we measured
endothelial-dependent vasodilating ability of Tg26 mouse thoracic aortas and the NO levels
in their plasma to access endothelial function.
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CHAPTER 2
COENZYME Q10 ALLEVIATES CHRONIC NUCLEOSIDE REVERSE
TRANSCRIPTASE INHIBITOR-INDUCED PREMATURE
ENDOTHELIAL SENESCENCE1
2.1. Introduction
Nucleoside reverse transcriptase inhibitors (NRTIs) have long been the backbone of
therapy for HIV infection. Though it is well-established that NRTI treatment results in
cardiovascular complications, the precise mechanism of toxicity has remained elusive. We
reported that NRTI treatment induces endothelial dysfunction in a murine model (Glover et
al., 2014; Jiang, Hebert, Zavecz, & Dugas, 2006; Jiang et al., 2010), and endothelial
dysfunction is a hallmark event in the pathogenesis of atherosclerosis (Widlansky, Gokce,
Keaney, & Vita, 2003). In cultured human endothelial cells, we demonstrated that NRTI
induced an endothelial injury resulting from oxidative stress (Glover et al., 2014; Jiang et al.,
2007; Jiang et al., 2010; Kline et al., 2009; Xue et al., 2013). This injury was coupled to an
increased release of endothelin-1 (ET-1) but decreased nitric oxide (NO) levels, suggesting a
disrupted ET-1/NO balance, an important marker for endothelial homeostasis (Glover et al.,
2014). In addition, we showed that acute NRTI treatment decreased mitochondrial electron
transport chain (ETC) activity and ATP levels while increasing reactive oxygen species
(ROS) production (Hebert, Crenshaw, Romanoff, Ekshyyan, & Dugas, 2004; Xue et al.,

This chapter was previously published as Yi-Fan Chen et al., “Coenzyme Q10 Alleviates
Chronic Nucleoside Reverse Transcriptase Inhibitor-Induced Premature Endothelial
Senescence,” Cardiovascular Toxicology (2019). Reprinted by permission of Springer Nature
Press.
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2013).
Oxidative stress is known to accelerate the onset of a senescent phenotype in endothelial
cells (Kurz et al., 2004). Moreover, NRTI-induced oxidative stress and mitochondrial damage
were shown associated with the onset of premature senescence in fibroblasts (Caron, Auclairt,
Vissian, Vigouroux, & Capeau, 2008). Intriguingly, cells with a prematurely senescent
phenotype exhibit a substantially increased lactate production (Unterluggauer et al., 2008),
and we reported that in endothelial cells, the ratio of lactate to pyruvate is increased in NRTIinduced mitochondrial dysfunction (Xue et al., 2013). Because the lactate-to-pyruvate ratio, a
glycolytic index, is an important marker for oxidative phosphorylation capacity (Clay,
Behnia, & Brown, 2001) and thus, mitochondrial bioenergetic function, increased glycolysis
in senescent cells suggests a link between senescence and mitochondrial dysfunction. In
addition, we reported that NRTI-induced oxidant injury leads to the autophagic degradation
of mitochondria, termed mitophagy, and a subsequently decompensated mitochondrial
biogenesis (Xue et al., 2013). This suggested that a prematurely senescent phenotype may
play a role in NRTI-induced endothelial dysfunction in vivo. We thus set out to investigate
whether chronic NRTI treatment induced endothelial senescence.
The excess production of mitochondrial-derived ROS has been considered a basis for
NRTI-induced endothelial dysfunction (Jiang et al., 2007). The overexpression of
mitochondrial antioxidant manganese superoxide dismutase (MnSOD) was shown to rescue
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short-term NRTI-induced endothelial dysfunction (Glover et al., 2014). However, chronic,
excess production of ROS may overwhelm endogenous antioxidant capacity, inducing a
sustained superoxide production that gives rise to endothelial dysfunction. Coenzyme Q10
(Q10) is well-known as an essential cofactor for the ETC and is a free radical scavenger
(Beyer, 1992). It can potentially preserve mitochondrial respiration by removing excess
mitochondrial ROS. Moreover, we showed that the acute toxicity of NRTI could be reversed
by treatment with Q10 (Xue et al., 2013). Thus, we hypothesized that the co-administration of
Q10 would alleviate NRTI-induced ROS production to prevent the premature senescence of
endothelial cells. The NRTIs manifest distinct cellular toxicities in a number of tissues, but
the data suggest that the mechanisms for their off-target toxicities may vary among the
individual NRTI compounds (Lund, Peterson, & Wallace, 2007; McComsey, Bai, Maa,
Seekins, & Wong, 2005). Therefore, we chose to compare NRTI from three subclasses for
this study: Zidovudine (AZT), a thymidine analogue, lamivudine (3TC), a cytidine analogue,
and tenofovir (TEN), an acyclic nucleotide analogue of adenosine.
2.2. Materials and Methods
2.2.1. Drugs and reagents
AZT and 3TC were obtained from Sigma-Aldrich (St. Louis, MO) and TEN was
purchased from Moravek Biochemicals (Brea, CA). Stock solutions containing NRTI were
prepared in deionized, distilled water and were diluted 1:1000 in cell culture media, such that
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the final concentration of each NRTI was 10 µM. The peak plasma concentration of these
NRTIs in HIV patients range from 0.7 to 9 μM (Child et al., 1991; Cressey et al., 2015; L. H.
Wang, Chittick, & McDowell, 1999). In addition, previous studies in our laboratory using
AZT, likely one of the most toxic of the NRTIs, showed dose-dependent increases in
endothelial ROS production at doses between 0.5 to 10 μM (Jiang et al., 2007). Therefore, the
final concentration of the each NRTI was rounded up to 10 µM, such that a direct comparison
could be made between the differing drugs. Q10 was purchased from Sigma-Aldrich, and
stock solutions prepared in ethanol were likewise diluted 1:1000 in cell culture media, such
that the final concentration was 5 µM.
2.2.2. Cell culture
Human aortic endothelial cells (HAEC) were obtained from Cell Applications (San
Diego, CA), and were cultured in MCDB 131 media containing 10% fetal bovine serum on
0.2% gelatin coated tissue culture plates. Six different isolates of HAEC were used for
experiments, with the isolates selected from non-smoking males and females having no
known complications from cardiovascular disease and of ages ranging from 41-65 years.
HAEC were incubated with 10 µM NRTI ± 5 µM Q10 continuously applied across passages,
and were split every 3-4 days at a ratio less than 1:4 (v:v).
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2.2.3. Population doubling
To determine the impact of NRTI on the cumulative number of population doublings,
HAEC were subjected to NRTI treatment across consecutive cell passages. The population
doubling level is the number of times that the inoculated cells are doubled to produce to the
harvested cell number. Cells were cultured until confluent for 2-12 passages, and at each subculture, cells were counted using a Vi-CELL XR Cell Viability Analyzer from Beckman
Coulter (Indianapolis, IN). Cumulative population doubling at each passage was calculated
from the cell count, as described elsewhere (Cristofalo, Allen, Pignolo, Martin, & Beck,
1998). The equation is “(log10(NH)-log10(NI))/log10(2)=X”, wher NI, NH, and X represent
inoculated cell number, harvested cell number, and population doublings, respectively.
2.2.4. Senescence-associated β-galactosidase cell staining
At each consecutive passage, HAEC were fixed and stained using a Senescence-β-Gal
Staining Kit (Cell Signaling Technology, Billerica, MA), following the manufacturer’s
recommended protocol. Cells staining blue were counted manually under light microscopy,
with cells exhibiting significant blue staining encompassing the majority of the cell body
counted as senescent. Cells with low intensity blue staining or with non-uniform staining
distributed in only one region of the cell were not considered senescent. Eight fields of view
were averaged per cell culture well.
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2.2.5. ROS production measurement
The mitochondria-selective fluorescent probe MitoSOX (Thermo Fisher, Waltham, MA)
was used to assess ROS production. Cells were treated as indicated, then incubated with 5
μM MitoSOX for 30 min and washed twice with warm phosphate-buffered saline. MitoSOX
fluorescence was assessed at Ex 510/Em 580 nm. Fluorescence measures in each well were
normalized to relative DNA content, determined using Hoechst 33342 dye.
2.2.6. Analysis of mitochondrial respiration
An XF24 Extracellular Flux Analyzer (Seahorse Bioscience, Agilent Technologies,
Santa Clara, CA) was used to determine mitochondrial function. One day before
measurements, HAECs were seeded with 50,000 cells per well in MCDB131 Complete
Medium in an XF24 cell culture microplate, except that control wells A1, B4, C3 and D6
contained no cells. The plate was incubated at 37°C in a humidified CO2 incubator overnight.
A sensor cartridge was hydrated with XF Calibrant in a utility plate at 37°C in a CO2-free
incubator overnight. On the day of measurements, the MCDB131 medium was replaced with
Seahorse assay medium containing 25 mM glucose. The cell culture plate was equilibrated at
37°C in a CO2-free incubator for 1 h. Oligomycin, FCCP and rotenone + antimycin A were
loaded into ports A, B and C of the cartridge, respectively. The final concentration of each
reagent was 1μM, 1 μM and 0.5 μM, respectively. The sensor cartridge was then loaded into
the XF24 Analyzer for calibration. After calibration, the utility plate was exchanged for the
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cell culture plate. The oxygen consumption rate (OCR) and extracellular acidification rate
(ECAR) for basal respiration were recorded before reagent injection. OCR of proton leak,
maximum OCR and non-mitochondrial oxygen consumption were measured as the oxygen
consumption rate over time for treatments with oligomycin, carbonyl cyanide-4(trifluoromethoxy)phenylhydrazone (FCCP), and rotenone + antimycin A injection,
respectively (Dranka et al., 2011).
2.2.7. Statistical analysis
Data were analyzed using GraphPad Prism software. All data were presented as group
means ± SEM and were compared using one- or two-way ANOVA, as appropriate. For
measures of population doubling (Figure 1) or percent senescent cells (Figure 3) assessed
over multiple passages from the same cell isolates, we utilized a repeated measures ANOVA.
In all cases, a value of p < 0.05 was considered statistically significant.
2.3. Results
2.3.1. Q10 co-treatment rescued the decreased population doubling rate induced by
NRTI
To test our hypothesis that chronic NRTI treatment promotes premature endothelial
senescence, we first evaluated population doubling (PD) in HAEC. The nature of the finite
replication capacity of primary HAEC provides a useful model for studying senescence. In all
three NRTI-treated groups, a significant decrease in PD was noted, beginning at passage 6
and continuing through passage 11 (Figure 2.1). Q10 is a component of the mitochondrial
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electron transport chain and contains the iron-sulfur clusters that serve both as electron
carriers and as a scavenging antioxidant. Co-treatment with Q10 rescued the decrease in PD
induced by chronic NRTI treatment. These results indicate that chronic NRTI treatment
induced early onset of decelerating population doubling that could be alleviated by coadministering Q10.

Figure 2.1. Q10 rescued NRTI-mediated decrease in population doubling observed after
chronic treatment. HAEC were treated with 10 µM AZT (A), 3TC (B), or TEN (C), with or
without 5 µM Q10 for 11 consecutive passages and cell numbers were counted. Population
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doubling was calculated as: PD=ln(Total Cells seeded/ Viable Cells)/ln(2). *p<0.05,
compared to equivalent passage control cells; #p<0.05, compared to Q10-treated cells;
φp<0.05, compared to NRTI-treated cells; repeated measures two-way ANOVA and Tukey
post-hoc were applied, n=3. Q10=Coenzyme Q10; HAEC=human aortic endothelial cells;
NRTI=nucleoside reverse transcriptase inhibitors; AZT=azidothymidine; 3TC=lamivudine;
TEN=tenofovir.
2.3.2. Q10 reduced the accumulation of senescent endothelial cells after chronic NRTI
treatment
To confirm that chronic NRTI treatment results in premature endothelial senescence, the
accumulation of senescence-associated β-galactosidase (SABG) was determined in HAEC
chronically treated with AZT, 3TC, or TDF. SAGB is one of the most widely used senescence
marker for in situ and in vitro analyses. The activity of SABG was detected at pH 6.0, the pH
at which X-gal is hydrolyzed by β-galactosidase to generate a blue product within senescent
cells (Figures 2.2 and 2.3). HAEC exhibited a significantly higher percentage of senescent
cells starting from passage 3 after treatment with AZT, from passage 4 with 3TC, and at
passage 8 with TEN treatments compared to passage-equivalent control cells (Figure 2.3A).
Co-treatment with Q10 abolished NRTI-induced accumulation of SABG, in that SABG
accumulation in NRTI treated cells was not different from passage-equivalent control cells.
However, cells treated with Q10 exhibited a lower SABG accumulation compared to control
cells at passages 7 and 8 (Figure 2.3B). These results indicate that chronic NRTI treatment
increases senescence markers and that Q10 co-treatment attenuates this accelerated
senescence.
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Figure 2.2. Senescence-associated β-galactosidase staining of endothelial cells. (A-H) HAEC
were treated with NRTI with or w/o Q10 chronically, and the accumulated senescenceassociated β-galactosidase (SABG) was detected by staining with X-gal. Senescent cells are
depicted by a dark green-blue color. Images shown are from passage 8 and are representative
of n=3 experiments.
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Figure 2.3. Q10 blocked the accumulation of senescent endothelial cells after chronic NRTI
treatment. (A) HAEC were treated with 10 µM of NRTI or (B) 10 µM NRTI + 5 µM Q10 for
8 passages. The cells were stained for SABG accumulation, and the number of senescent cells
were counted. *p<0.05, compared to passage-equivalent control cells; repeated measures
two-way ANOVA and Dunnett post-hoc were used, n=3. SABG=senescence-associated βgalactosidase. Images shown are representative of cells treated across 8 passages.

2.3.3. Q10 attenuated NRTI-mediated increase in mitochondrial ROS production
In our prior studies, short-term NRTI treatment increased mitochondrial ROS production
in endothelial cells. To investigate the cause of chronic NRTI-induced premature senescence,
ROS production was measured in HAEC treated chronically with NRTI. Chronic AZT, 3TC,
or TEN treatment increased mitochondrial ROS production from passage 6 to passage 10
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(Figure 2.4A). However, co-treatment with Q10 reduced NRTI-mediated increase in mtROS
(Figure 2.4B). These results suggest that co-treatment of cells with Q10 can potentially
moderate excess mtROS production induced by chronic NRTI treatment.

Figure 2.4. Q10 diminished NRTI-induced increase in mitochondrial ROS production after
chronic treatment. (A) HAEC were treated with 10 µM NRTI for 10 passages. ROS
production was determined using the MitoSOX fluorescent indicator and the data were
normalized to DNA content. Data are expressed as percent increase compared to controls. (B)
HAEC were treated with 5 µM of Q10 ± 10 µM NRTI for 8 passages. ROS production was
determined as in (A). *p< 0.05, compared to equivalent passage control cells; repeated
measures two-way ANOVA and Dunnett post-hoc were used, n=3-4.
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2.3.4. Q10 rescued the suppressed ATP-linked respiration and glycolytic flux induced by
chronic NRTI
Next, we aimed to investigate whether the increase in mitochondrial ROS production
observed after chronic NRTI treatment is associated with an alteration in mitochondrial
function. An XF24 Extracellular Flux Analyzer was used to access mitochondrial respiratory
function in HAEC treated chronically with AZT, 3TC or TEN. ATP-linked respiration
decreased in all three NRTI treatment groups (Figure 2.5A-D), especially in the AZT-treated
cells, which exhibited a dramatic decline. Meanwhile, TEN-treated cells also exhibited a
decline in basal and maximal respiration. Therefore, we tested whether Q10 co-treatment
improved the cellular respiration rate observed after NRTI treatment (Figure 2.5C, D).
Intriguingly, chronic co-treatment with Q10 not only reversed the AZT-induced decline in
ATP-linked respiration but also increased maximal respiration (Figure 2.5D).
Based on this result, we tested whether chronic NRTI treatment affects bioenergetic function
in HAEC. In endothelial cells, glycolytic flux is reportedly the predominant bioenergetic
pathway contributing to ~85% of the total cellular ATP production (De Bock et al., 2013). To
examine the metabolic change induced after chronic AZT±Q10 treatment, we monitored
ECAR, which is used as an indicator for the rate of glycolysis (Figure 5E). After chronic
treatment, the ECAR level was higher in Q10 and AZT+Q10 treated groups compared to
AZT-treated HAEC. This result demonstrates that Q10 may prevent the decline in glycolytic
flux caused by chronic AZT treatment.
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Figure 2.5. Q10 rescued NRTI-mediated suppression in ATP-linked respiration and the
reduction in glycolytic flux after chronic treatment. (A-B) HAEC were treated with 10 μM
NRTI as indicated for 10 passages and OCR was measured using an XF24 Extracellular Flux
Analyzer. Oligomycin (Oligo), FCCP, and Antimycin A with Rotenone (AA/R) were added
(as indicated by arrows) to assess rates of basal respiration, ATP-linked respiration, maximal
respiration, reserve respiration, and proton leak. (C-E) HAEC were treated with 10 μM AZT,
5 μM Q10, or both for 10 passages and OCR and ECAR were measured. *p < 0.05, compared
to the control group; #p < 0.05, compared to AZT-treated cells; respiration rate was compared
by using one-way ANOVA at each respiratory state with Dunnett post-hoc, n=3-5.
OCR=oxygen consumption rate; ECAR= extracellular acidification rate.
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2.4. Discussion
Effective antiretroviral therapy has transformed HIV-1 infection from a fatal disease into
a manageable but chronic condition demanding long-term administration of multiple drugs.
However, the long-term administration of antiretroviral therapies has the potential to induce
metabolic disruptions, such as hyperlipemia, insulin resistance and abnormalities in glucose
metabolism, and has been shown to increase the risk for developing chronic cardiovascular
diseases (CVD) among HIV patients (Freiberg et al., 2013; Islam, Wu, Jansson, & Wilson,
2012). We and others have shown that NRTI treatment results in endothelial dysfunction both
in vitro and in vivo (Jiang et al., 2006; Kline & Sutliff, 2008). Oxidative stress, and even
mitochondrial oxidative stress, are known contributors to endothelial dysfunction and NRTI
are recognized mitochondrial toxicants. Therefore, NRTI-induced mitochondrial oxidant
injury may be a mechanism contributing to this drug-mediated endothelial dysfunction.
However, the mechanism underlying NRTI-induced endothelial dysfunction and the chronic
impact of NRTI treatment on mitochondria remains unclear. Thus, identifying a possible
mechanism contributing to NRTI-induced endothelial dysfunction and potentially developing
an adjunct therapy for reducing this dysfunction should be helpful in improving outcomes for
antiretroviral therapy.
Functionally, mitochondrial respiration can be divided into electron transport and
oxidative phosphorylation operating through the actions of complexes I-IV (Huttemann, Lee,
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Samavati, Yu, & Doan, 2007; Lenaz et al., 2010). We previously reported suppressed
activities of complexes I-IV, decreased ATP production, and a stimulation of mitophagic
activity 6-8 h after NRTI treatment, but these acute impairments recovered 24-48 h after
dosing (Xue et al., 2013). Our earlier findings thus suggested that the antioxidant system
within mitochondria and repair via mitophagy may successfully compensate for the excess
ROS produced after acute NRTI, but the impact of chronic NRTI administration was yet to be
elucidated. It is well established that oxidative stress promotes ROS signaling in many
pathologies, especially in aging-related diseases (Droge & Schipper, 2007). Previously, we
found that NRTIs induce an increase in both cellular and mitochondrial ROS production, but
this injury did promote apoptosis (Jiang et al., 2007; Jiang et al., 2010). Since oxidative stress
is a known driving force for cellular senescence, we hypothesized that chronic NRTI
treatment promotes premature endothelial senescence but that co-treatment with the
mitochondrial antioxidant Q10 would block this progression.
In this study, HAEC chronically administered AZT, 3TC, or TEN exhibited a decreased
PD and an increased senescent cell accumulation. At the same time, the production of mtROS
increased across NRTI treatment groups. These findings suggested that chronic NRTI
treatment induces excess mtROS production and promotes endothelial senescence. In support
of our findings in endothelial cells, zidovudine (AZT) was reported to induce senescence in
immortalized cancer cells, presumably by inhibiting telomerase activity (H. Wang, Zhou, He,
63

Dong, & Liu, 2017). In addition, stavudine and zidovudine, but not abacavir, didanosine,
lamivudine nor tenofovir, induced mitochondrial dysfunction and senescence in human
primary fibroblasts (Caron et al., 2008). Tenofovir and emtricitabine promoted mitochondrial
stress and premature senescence in human lung and cardiac fibroblasts in an mTORC1dependent pathway (Nacarelli, Azar, & Sell, 2016). Taken together, these reports suggest that
NRTIs of varying types induce premature senescence in a number of cell types. Although
specific drugs among the class of NRTI may induce senescence via differing mechanisms, a
commonality among these reports is that mitochondrial dysfunction seems to prime cells for
undergoing premature senescence. Thus, the premature induction of endothelial senescence
may contribute to NRTI-induced vascular dysfunction.
An imbalance in mitochondrial function is a common predisposing factor for vascular
diseases. For example, endothelial senescence is associated with an impairment of
mitochondrial biogenesis and an alteration in the expression of the mitochondrial components
transcribed from mitochondrial DNA (mtDNA) (Dai, Rabinovitch, & Ungvari, 2012).
Previously, we observed decreases in ETC complex I-IV activity after acute NRTI treatment
(Xue et al., 2013). In this study, all three treatment groups exhibited a suppression in ATPlinked respiration. ATP-linked respiration is mediated by oxidative phosphorylation. Its
decline could be owing to low ATP demand, low substrate availability, or ETC damage (Hill
et al., 2012). Although ATP demand in endothelial cells is accommodated mainly via
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glycolysis, in studies presented here, 25 mM glucose was supplied in the analysis medium to
provide a carbon source for the cells. Therefore, an ETC inhibition seems the most likely
cause for NRTI-induced reductions in ATP-linked respiration. In addition to these findings,
TEN treatment resulted in a reduction in basal and maximal respiration that was not observed
for 3TC or AZT treated cells. We do not have an explanation for these results, except to
suggest that perhaps its mechanism of injury within mitochondria may be more complex than
for the other two drugs. On the other hand, in AZT-treated cells, there was an increase in
reserve respiration. However, the reserve respiration capacity (RRC) is the mathematical
difference between maximal and basal respiration. Since AZT did not simultaneously
increase the maximal respiration rate, the observed AZT-mediated increase in RRC could
have simply resulted from a decreased level of basal respiration.
Because endothelial cells depend primarily on glycolysis for their ATP, the observed
disturbance in mitochondrial respiration after NRTI treatment likely impacts endothelial
function mainly through an alteration in redox signaling, rather than by reducing their ATP
production. Mitochondria are the major intracellular source of ROS, even in endothelial cells,
where they regulate signaling in numerous physiological and pathological processes,
including inflammation (Pamukcu, Lip, & Shantsila, 2011). Therefore, targeting
mitochondrial redox signaling is an emerging therapeutic strategy for numerous pathologies
(McCarthy & Kenny, 2016).
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Q10 is both a free radical scavenger and an important cofactor for electron transport
(Beyer, 1992; Ernster & Dallner, 1995). It may thus preserve mitochondrial respiration and
function by removing excess mitochondrial ROS. Interestingly, Q10 co-treatment attenuated
NRTI-mediated inhibition in population doubling and the accumulation of senescent cells and
mtROS. The bioenergetic result here indicates that Q10 administered together with AZT not
only rescued ATP-linked respiration, but also elevated the reserve and maximal respiration
capacities. RRC fluctuates according to cellular ATP demands, helping the cells cope with
acute insults or increased workload. Bioenergetic reserve respiration varies among cell types,
but an increase in substrate availability, mitochondrial mass, and good ETC integrity typically
expands its capacity. The mitochondrion is the only organelle equipped with its own genome,
mtDNA. Thus, a decrease in mtDNA abundance or mtDNA mutations would critically impair
mitochondrial ETC integrity. In support of this assertion, NRTI-induced mtDNA depletion
was reported in adipocytes isolated from HIV patients, and this outcome associated with
subcutaneous fat wasting (Nolan et al., 2003). Further study may thus be required for fully
elucidating the impact of chronic NRTI treatment on the integrity of mtDNA.
It was peculiar that Q10 treatment together with AZT, but not Q10 treatment alone,
increased RRC, perhaps suggesting the effect of co-treatment on HAEC may be more
complicated than simply eradicating NRTI-induced ROS. This outcome led us to consider
whether chronic use of Q10 with AZT induces a metabolic switch that increases RRC. Since
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endothelial cells are glycolytic, monitoring glycolytic flux, quantified by measuring glucose
uptake and lactate excretion, represents a good estimation for their metabolic status. Using
the Seahorse XF analyzer, we thus used an ECAR measurement to assess the excretion of
lactic acid per unit time into cell culture media (Wu et al., 2007). The observed increases in
ECAR measured in the Q10 and Q10+AZT treatment groups could suggest that Q10 elevates
the metabolic status of endothelial cells. However, the production of carbon dioxide via
respiration can also contribute to the acidification of the medium, thus complicating the
interpretation of data (Mookerjee, Goncalves, Gerencser, Nicholls, & Brand, 2015).
Nevertheless, these findings may suggest a future direction of study, investigating a switch in
the metabolic status of senescent endothelial cells and a thorough elucidation of the role of
Q10 as an anti-aging supplement.
In summary, here we demonstrate that chronic NRTI treatment induces premature
senescence and decreases mitochondrial bioenergetic function in endothelial cells. Taken
together, these findings suggest a potential interaction between NRTI-induced mitochondrial
damage and endothelial cell senescence, which may contribute to the mechanism of NRTI
toxicity. A limitation of this study is that we did not examine the effect of chronic NRTI
treatment on the mitochondrial genome, and damage to the mitochondrial genome is known
to exacerbate cellular aging (Pinto & Moraes, 2015). Evaluating NRTI induced effects on
mtDNA copy number, mtDNA damage level, or mtDNA sequencing and the impact of Q10
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co-treatment will be helpful in identifying possible mutation site(s) on mtDNA to derive a
better understanding of NRTI pathogenesis. Importantly, our findings suggest Q10 as a
possible candidate for adjunct therapy to alleviate the vascular side effects arising from
chronic NRTI usage, but in vivo confirmation of these in vitro findings will be necessary.
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CHAPTER 3
CHRONIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR
TREATMENT DISRUPTS MITOCHONDRIAL HOMEOSTASIS AND
PROMOTES PREMATURE ENDOTHELIAL SENESCENCE
3.1. Introduction
The launch of combination antiretroviral therapy (cART) has effectively reduced
mortality and improved the life expectancy of human immunodeficiency viral (HIV)-infected
patients. Therefore, the clinical management of HIV infection has shifted from acute
opportunistic infection to chronic comorbidities, such as hyperlipidemia, kidney dysfunction,
and cardiovascular disease (CVD) (Gallant, Hsue, Shreay, & Meyer, 2017). Numerous
epidemiologic studies have shown that both HIV infection and cART contribute to CVD risk
(Friis-Moller et al., 2016; Friis-Moller et al., 2003; Group et al., 2008). Nucleoside reverse
transcriptase inhibitors (NRTIs) that form the backbone of cART exhibit toxicities in
numerous tissues but with an as yet unclear mechanism (Kohler & Lewis, 2007). Since
people living with HIV (PLWH) require long-term treatment, monitoring for possible NRTIassociated tissue injuries is vital.
Our laboratory reported that NRTIs induce endothelial dysfunction in vivo and
promote neointimal hyperplasia and increased intima-media thickness (Jiang, Hebert, Zavecz,
& Dugas, 2006; B. Jiang et al., 2010). Endothelial dysfunction is a hallmark and an initiating
event in atherosclerosis, and increased intima-media thickness is correlated with increased
CVD risk. NRTI-induced endothelial dysfunction was linked with endothelial oxidative stress
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and mitochondrial dysfunction in vitro (Jiang et al., 2007; Kline et al., 2009). Additionally, in
human umbilical vein endothelial cells (HUVEC), our group reported that NRTIs decreased
the activity of mitochondrial electron transport chain (ETC) complexes while increasing
reactive oxygen species (ROS) production 6-8 hours after a single treatment (Xue et al.,
2013). In the same study, we also noted a rise in mitophagic activity 8 hours after zidovudine
(AZT) treatment. Mitophagic activity is reportedly reduced during the senescence of cells
intimately involved in the pathogenesis of numerous diseases (Araya et al., 2019; Ito et al.,
2015). Therefore, investigating the chronic impact of NRTI treatment on endothelial
mitochondria and mitochondrial bioenergetics may help to elucidate mechanisms for the
elevated CVD risk associated with cART.
The clinical side effects of NRTIs, including myopathy, peripheral neuropathy, and
lipoatrophy, are believed to result from their mitochondrial toxicity (Scruggs & Dirks Naylor,
2008; Shikuma et al., 2001; Simpson & Tagliati, 1995). Mitochondria are highly dynamic
organelles that utilize processes such as biogenesis, fission, fusion, and mitophagy to
maintain their homeostasis and proper function (Palikaras & Tavernarakis, 2014). The
regulation of these mechanisms is critical for cellular adaptive responses to intracellular or
environmental stressors. Mitochondrial toxicity can result from an interruption in fission and
fusion, imbalance of biogenesis and mitophagy, mitochondrial DNA depletion or mutation, or
dysregulation of cell death pathways. Long-term exposure to AZT and other NRTIs increase
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cellular and mitochondria-specific superoxide and decrease mitochondrial membrane
potential, suggesting NRTIs induce mitochondrial dysfunction in endothelial cells (Kline et
al., 2009). However, how endothelial mitochondria regulate their dynamics and shift the “cell
fate” decision in response to long-term NRTI treatment has not been well delineated.
Mitochondria are recognized contributors to aging and age-related pathologies.
Numerous mitochondrial events that promote senescence such as excessive ROS production
and a dysregulation of mitochondrial dynamics, bioenergetics, mitochondrial DNA integrity,
and calcium homeostasis have been broadly discussed (Lauri, Pompilio, & Capogrossi, 2014;
Ziegler, Wiley, & Velarde, 2015). Excessive oxidative stress reportedly accelerates the onset
of a senescence phenotype in endothelial cells (Kurz et al., 2004). Moreover, in fibroblasts,
long-term exposure to thymidine analog-type NRTIs increase oxidative stress and induce
mitochondrial changes, resulting in an early onset of senescence (Caron, Auclairt, Vissian,
Vigouroux, & Capeau, 2008). Therefore, we hypothesized that chronic NRTI treatment
disrupts mitochondrial homeostasis and causes premature senescence in endothelial cells that
may predispose PLWH to CVD. In the current study, we treated human aortic endothelial
cells (HAEC) chronically with emtricitabine (FTC), a cytidine analog, or tenofovir (TEN), an
acyclic nucleotide analog, or a combination of both to examine their mitochondrial function.
In addition, we utilized Tg26, an HIV-1 transgenic mouse strain, to investigate the possible
synergistic effect of viral proteins and chronic NRTI treatment on vascular function in vivo.
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3.2. Materials and Methods
3.2.1. Drugs and reagents
Emtricitabine (FTC) was obtained from TCI AMERICA (Portland, OR) and tenofovir
(TEN) was purchased from Sigma-Aldrich (St. Louis, MO). NRTI stock solutions were
prepared in deionized, distilled water and were diluted 1:1000 in MCDB 131 media (SigmaAldrich) containing 10% fetal bovine serum (FBS). In accordance with the reported peak
steady state concentrations for FTC and TEN in serum or plasma (0.70~10.11 μM), we
selected 10 μM as the working dose for our in vitro study (Chittick et al., 2006; de Lastours,
Fonsart, Burlacu, Gourmel, & Molina, 2011). For our in vivo study, we utilized the body
surface area normalization method to extrapolate the recommended human dose (200 mg/day
FTC and 300 mg/day tenofovir disoproxil fumarate (TDF)) for dosing in mice (Masho, Wang,
& Nixon, 2007). The dose translation formula is “Human equivalent dose (mg/kg) = Animal
dose (mg/kg) * Mouse Km/ Human Km”. Thus, the selected doses in mice were 40 mg/kg
FTC and 50 mg/kg TDF, with the drugs administered in drinking water. Drug concentrations
applied to the water were determined by their estimated water consumption determined
gravimetrically. To estimate the impact of chronic NRTI treatment, mice were dosed for 12 to
14 wk.
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3.2.2. Cell culture
Human aortic endothelial cells (HAEC) were purchased from Cell Applications, Inc.
(San Diego, CA). The cell donor was a 55-year-old male with no smoking history nor known
complications from CVD. HAEC were cultured and maintained on 0.2% gelatin-coated tissue
culture flasks or plates with MCDB 131 media containing 10% FBS (GenClone, San Diego,
CA). HAEC were incubated with 10 µM FTC and/or TEN continuously applied across
passages and were split every 3-4 days after reaching 70-90% confluency. Endpoints were
assessed in cells maintained in NRTI-containing medium for 1 to 3 passages (denoted as
early-passage cells) or for 8 to 10 passages (late-passage cells).
3.2.3. Animals
HIV transgenic mice (Tg26) raised on a C57BL/6 background were kindly provided by
Dr. Roy Sutliff at Emory University. The original Tg26 strain, FVB/N-Tg(HIV)26Aln/Pkltj,
expressed a mutant HIV-1 provirus deleted in the gag and pol region, rendering the virus
replication-incompetent (Bruggeman et al., 1994). The Tg26 expresses several HIV-1 viral
proteins in numerous tissues, though not in the circulation or peripheral blood mononuclear
cells (Carroll et al., 2016; Kopp et al., 1992; Lu, He, & Klotman, 2006; Ray & Hu, 2011).
Given the renal complications of the original strain, the Sutliff laboratory back-crossed the
mice onto a C57BL/6 background, rendering the mice stable, healthy, and robust, thus
increasing the feasibility of experiments assessing the impact of chronic NRTI treatment on
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vascular reactivity. The breeding colony was maintained in an AALAC-accredited animal
facility at LSU. Use of animals followed guidelines set forth by the Office of Laboratory
Animal Welfare and were approved by the LSU Institutional Animal Care and Use
Committee. Both male and female mice were included, with each sex distributed as evenly as
possible across treatment groups. Dosing of animals was initiated at 8-10 months of age.
3.2.4. Quantitative PCR
At increasing passage numbers, DNA was isolated using Geno PlusTM Genomic DNA
Extraction Miniprep System from Viogene (Taipei, Taiwan), and 10 ng DNA from each
sample was used for reactions. TaqMan-based qPCR was performed as described by Carlisle
et al.(Carlisle, Rhoads, Aw, & Harrison, 2002). The conserved D-loop region of
mitochondrial DNA was used to design a pair of primers (forward, 16421-16434; reverse,
16463-16486). To estimate mtDNA copy number, this was coupled to a TaqMan probe
(16439-16460) containing a reporter dye (FAM, 6-carboxyfluorescein) at the 5’ terminus and
a quencher dye (TAMRA, 6-carboxytetramethylrhodamine) at the 3’ terminus. The primers
and TaqMan probe were synthesized by IDT (San Diego, CA). Human RNase P gene was
used to determine the nuclear genome copy number. TaqManTM RNase P Detection Reagents
kit (Thermo Fisher Scientific, Waltham, MA) was used for this purpose. Reactions were
mixed with DNA sample, primers/probes, and iTaq Universal Probe Supermix (Bio-Rad,
Hercules, CA). The PCR cycle was performed in an ABI Prism 7300 Real-Time PCR system
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(Applied Biosystems, Foster City, CA). Data are expressed at the ratio of mitochondrial-tonuclear genome copy number.
3.2.5. Senescence-associated β-galactosidase cell staining
HAEC were treated with 10 µM FTC, 10 µM TEN, or a combination of FTC and TEN
applied continuously through passages 2-14. Cells were prepared in 6-well plates, then fixed
and stained using a Senescence-β-Gal Staining Kit (Cell Signaling, Billerica, MA).
Senescence-associated β-galactosidase (SABG) was detected using x-gal, an indoxyl
glycoside that produces insoluble blue molecules upon hydrolysis by β-galactosidase. A
thousand cells were counted per well under light microscopy, and cells exhibiting significant
blue staining in the majority of cytoplasm were considered senescent. The data were
expressed as the percentage of blue-stained (senescent) cells over a thousand total cells
analyzed.
3.2.6. ROS production measurement
Dihydrorhodamine 123 (DHR123; Thermo Fisher) was used to detect cytosolic ROS
production. Cells were treated with NRTI, then incubated with 10 μM DHR123 for 20 min
and rinsed twice with warm HBSS. DHR123 fluorescence was measured at Ex 485/Em 528
nm. Fluorescence assessed in each well was normalized to DNA content, determined using
0.2 μg/ml Hoechst 33342 dye (MP Biomedicals, Santa Ana, CA) at Ex 350/Em 461 nm.
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3.2.7. Western blot analyses
Levels of p21, p53, LC3A/B, Parkin, and Bnip3L/Nix (Nix) were assessed using western
blot analysis. Cells were homogenized on ice in lysis buffer containing a protease inhibitor
cocktail, and protein concentrations were determined using a BCA protein assay (Thermo
Fisher). Equal volumes of protein were subjected to SDS-PAGE (Novus Biologicals,
Centennial, CO) under reducing conditions, after which the proteins were transferred to
PVDF membranes. Membranes were blocked with 5% bovine serum albumin and incubated
overnight with primary antibody against p21, p53, LC3A/B, Parkin, Nix (1:1000; Cell
Signaling), and GAPDH (1:500, Santa Cruz, Dallas, TX) or actin (1:1000; Sigma-Aldrich).
Membranes were then incubated with horseradish peroxidase-conjugated anti-rabbit or antimouse IgG, and protein bands were visualized using enhanced chemiluminescence.
Densitometric analysis was performed using ImageJ software (National Institutes of Health),
and data were normalized to GAPDH or actin.
3.2.8. Immunofluorescence microscopy
HAEC were plated on 0.2% gelatin-coated coverslips and were incubated with 100 nM
MitoTracker Deep Red FM (MTDR, Thermo Fisher Scientific) in serum-free MCDB131
media for 30 min. The sample was rinsed twice with PBS and then fixed by 4%
paraformaldehyde, permeabilized with 0.05% NP-40 in PBS, blocked in 3% goat serum, and
detected with primary antibodies. The following antibodies were used: rabbit anti-LC3A/B
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(1:200, Cell Signaling), rabbit anti-Nix (1:100, Cell Signaling), rabbit anti-Parkin (1:100,
Proteintech, Rosemont, IL), and goat anti-rabbit fluorescein isothiocyanate (FITC)
conjugated IgG (Santa Cruz). Samples were mounted using ProLong Gold Antifade Mountant
with 4’,6-diamidino-2-phenylindole (DAPI) (Thermo Fisher) and then observed under a Zeiss
Axio Observer Z1 fluorescence microscope (Oberkochen, Germany).
3.2.9. Analysis of mitochondrial respiratory function
Mitochondrial respiration (oxygen flow, IO2) was measured by high-resolution
respirometry using Oxygraphy-2K (Oroboros Instruments, Innsbruck, Austria) in HAEC.
With slight modifications, a standardized substrate uncoupler inhibitor titration (SUIT)
protocol at 37°C was used (Boyle, Zheng, Anderson, Neufer, & Houmard, 2012). HAEC
were trypsinized and rinsed, then resuspended in a mitochondrial respiration medium, MiR05
(Oroboros), and transferred into two independent oxygraphy chambers (1-2*106
cells/2mL/chamber) for duplicate measurements. Routine respiration was measured before
HAEC permeabilization by adding digitonin (~7.5-10 µg/106 cells) for 5 to 10 min. In the
absence of ADP, 5 mM pyruvate and 2 mM malate were added to stimulate leak respiration
from ETC complex I (PML). Next, a saturating concentration of ADP (2.5 mM) was added to
stimulate maximal oxidative phosphorylation (OXPHOS) capacity from ETC complex I
(PMP). Subsequently, 10 µM cytochrome c was added to access mitochondrial membrane
integrity (PMCytC) (note: a subset of samples was performed using 20 µM cytochrome c), and
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10 mM glutamate was added to further examine complex I OXPHOS (PMGP). Then,
maximal OXPHOS from ETC complex I&II was evaluated by adding 10 mM succinate
(PMGSP). An uncoupling agent, carbonyl cyanide m-chlorophenyl hydrazine (CCCP), was
next titrated at ~0.5 µM per step to measure maximal respiration arising from convergent
electron flow through ETC (PMGSE). Lastly, 2.5-5 mM antimycin A was added to measure
residual oxygen consumption. The IO2 in HAEC SUIT was acquired and calculated using
DatLab software (Oroboros Instruments), after correcting for residual oxygen consumption
and normalizing per million cells (pmol/s/106 cells). All measurements were corrected for
daily room air calibrations as well as instrumental background and associated zero
calibrations. Approximately 15% of the samples were analyzed in the absence of cytochrome
c. Approximately 10% of samples were excluded due to technical difficulties (e.g., samples
were not viable, titration errors).
In an exploratory analysis, extensor digitorum longus (EDL) muscles were collected
using convenience sampling from a subset of mice that were being euthanatized to collect the
abdominal aortas described in this study. The EDL muscles were placed in ice-cold BIOPs
buffer. Subsequently, the EDL muscle were further dissected on ice under stereo-microscopy
to acquire small fiber bundles. The 1-3 mg fiber bundles were then placed in fresh ice-cold
BIOPS buffer with 50 ug/mL of fresh saponin and placed on an orbital shaker for 30-min to
permeabilize the plasma membrane. The fiber bundles were then washed in ice-cold MiR05
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for ~15 min. The fiber bundles were then blotted dry (40s) on Whatman paper and weighed
on an analytical balance (Mettler Toledo) to the nearest 0.01 mg. Fiber bundles (~1-3 mg)
were placed into independent oxygraphy chambers. Due to the nature of the convenience
sampling the muscle fiber analyses were only performed in singlets and should be viewed as
exploratory. We used a similar SUIT protocol as described for the HAEC with slight
modifications to measure the respiratory states in the saponin-permeabilized muscle fibers.
The respiratory measurements were made with O2 concentrations between ~425 to 200 nM
O2. Specifically, the LEAK respiration was measured at ~200 nM O2 and OXPHOS
measurements were made at ~400-300 nM O2. In the absence of ADP, 5 mM pyruvate and 2
mM malate were added to stimulate PML. Next, a saturating concentration of ADP (5 mM)
was added to stimulate PMP. In addition, 20 µM cytochrome c was added to access
mitochondrial membrane integrity (PMCytC), and 10 mM glutamate was also added to
stimulate PMGP. Then, 10 mM succinate was added to stimulate PMGSP. An uncoupling
agent, CCCP, was next titrated at ~0.5 µM per step to stimulate PMGSE. Lastly, 2.5-5 mM
antimycin A was added to measure residual oxygen consumption. The O2 flux (JO2) in the
permeabilized muscle fibers was acquired and calculated using DatLab software (Oroboros
Instruments), after correcting for residual oxygen consumption and normalizing per mg wetweight (pmol/s/mg). All measurements were corrected for daily room air calibrations as well
as instrumental background and associated zero calibrations. Three samples were excluded
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due to a positive cytochrome c effect (>15% increase in respiration upon addition of
cytochrome C) and one sample was excluded as a statistical outlier.
To assess ATP production, HAEC grown in 96 well plates were treated as indicated.
DNA content was determined using 0.2 μg/ml Hoechst 33342 dye (MP Biomedicals) at Ex
350/Em 461 nm before assessing the levels of ATP using the CellTiter-Glo Luminescent Cell
Viability Assay kit (Promega, Madison, WI). Luminescence measured in each well was
normalized to DNA content.
3.2.10. Measures of vascular reactivity
Vascular reactivity was assessed using a Wire Myograph System-520 A from DMT
(ADInstruments, Sydney, Australia) as previously described (Glover et al., 2014). Mice were
anesthetized and exsanguinated to ensure euthanasia. The thoracic aorta was extracted and
kept in Krebs Henseleit solution at 37 °C, pH 7.4, throughout the experiment. The adipose
and connective tissues were removed from the vessel carefully. To record vascular tension, a
short aortic ring (~ 1.7-2 mm) was hung on two 40 μm-stainless steel wires and then mounted
onto a pair of jaws that interfaced to a force transducer and PowerLab with LabChart
software (ADInstruments). Baseline tension was set at 9.8 mN/mm, and the aortic ring was
equilibrated for 1 h before vasoconstriction was induced using phenylephrine. Increasing
doses of acetylcholine (Ach) were titrated in the buffer bath to induce endothelium-dependent
relaxation.
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3.2.11. Assays for endothelium-derived vasoactive factors
Levels of Vascular Cell Adhesion Molecule-1 (VCAM-1) were measured in HAEC
conditioned media using DuoSet® Human VCAM-1/CD106 ELISA kits from R&D Systems
(Minneapolis, MN). Nitric oxide (NO) levels in mouse plasma were measured using the
chemiluminescent Sievers Nitric Oxide Analyzer 280i interfaced to NOAnalysis Liquid
Software from GE (Boulder, CO), as described in our prior report (Xue et al., 2013) and as
outlined by Venkatesh et al. (Venkatesh et al., 2010).
3.2.12. Statistical analysis
Results were analyzed using GraphPad Prism software. All data are shown as means ±
SEM and were compared using one- or two-way ANOVA, as appropriate, with Dunnett’s or
Newman Keuls post-hoc. For comparison between early and late passages, or over multiple
passages from the same cell isolates, a repeated measures two-way ANOVA was utilized. In
all cases, a value of p < 0.05 was considered statistically significant.
3.3. Results
3.3.1. Long-term NRTI dosing induced oxidative stress and fluctuations in
mitochondrial DNA copy number in HAEC
In prior studies, our group reported that acute NRTI-induced mitochondrial dysfunction
and excessive ROS production in endothelial cells recovered to baseline levels by 24 to 48
hours after treatment (Jiang et al., 2007; Xue et al., 2013). Here, we examined NRTI-induced
endothelial injury and ROS production after chronic treatment. VCAM-1 is a reliable
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biomarker for endothelial activation induced by several mediators, including ROS. It is used
as a biomarker for CVD, including atherosclerosis, and as a surrogate marker for druginduced vascular injury (Zhang, Defelice, Hanig, & Colatsky, 2010). Moreover, with chronic
endothelial activation, endothelial dysfunction, associated with decreased endothelial nitric
oxide synthase (eNOS) activity or NO bioavailability has been reported (Gryglewski, Palmer,
& Moncada, 1986; Yoshizumi, Perrella, Burnett, & Lee, 1993). VCAM-1 levels in HAEC
conditioned media were elevated in late compared to early passage cells, and FTC and TEN
co-treatment induced an even higher level of VCAM-1 (Fig. 3.1A). In addition, ROS
production was increased in late-passage HAEC, particularly in the NRTI-treated groups
(Fig. 3.1B). ROS-mediated mtDNA damage and mitochondrial dysfunction have been
reported in vascular endothelial cells in vitro (Ballinger et al., 2000). In addition, studies have
shown that mtDNA copy number declines with age (Gadaleta et al., 1992; Mengel-From et
al., 2014). Therefore, we set out to measure mtDNA copy number over increasing passages of
cells undergoing chronic NRTI treatment (Fig. 3.2). In the first passage (P1), mtDNA copy
number exhibited variable responses to the differing NRTI treatments, with TEN increasing
mtDNA copy number, but TEN+FTC treatments significantly reducing mtDNA copy number.
In P6 and P10, all NRTI-treated groups exhibited a diminished mtDNA copy number
compared to passage-equivalent vehicle controls. These results suggest a higher level of
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endothelial injury, oxidative stress, and mtDNA damage in chronic NRTI treated endothelial
cells.

Figure 3.1. VCAM-1 levels and ROS production were elevated in chronic NRTI treated
HAEC. HAEC were treated with 10 μM of the indicated NRTI for 10 passages. (A) VCAM-1
levels were measured in conditioned media using ELISA and were normalized to total cell
protein content. (B) ROS production was determined as DHR fluorescence and was
normalized to DNA content estimated using Hoechst33342 staining. Data are expressed as %
increase compared to early passage VEH. *p<0.05, compared to early VEH; #p<0.05,
compared to late VEH; n=3. Abbreviations: VEH, vehicle; FTC, emtricitabine; TEN,
tenofovir.
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Figure 3.2. Chronic NRTI treatment decreased mtDNA copy number in HAEC. HAEC were
treated with 10 μM of the indicated NRTI for 14 passages. Mitochondrial DNA (mtDNA)
copy number was measured using quantitative real-time PCR conducted using a conserved
fragment of D-loop and normalized to a single-copy nuclear gene RNase P. Results are
expressed as fold change of each indicated passage and each treatment relative to vehicletreated P1. *p<0.01, compared to passage-equivalent VEH; n=3.

3.3.2. Chronic NRTI treatment augmented the accumulation of senescence markers
To test our hypothesis that chronic NRTI treatment results in premature endothelial
senescence, we used the accumulation of β-galactosidase and p53 and p21 expression levels
to examine senescence after chronic maintenance in FTC and/or TEN. SABG is widely used
as a senescence biomarker, providing in situ evidence of senescent cell accumulation (Dimri
et al., 1995). We observed a higher percentage of senescent cells in HAEC after chronic NRTI
treatment (Fig. 3.3A). The p53-p21 signaling axis is broadly known as a molecular pathway
for senescence; p21 is transcriptionally up-regulated by p53, and then triggers G1-phase cell
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cycle arrest by inhibiting Cdk2 and Cdk4 (Ben-Porath & Weinberg, 2005). Intriguingly, there
was a higher p53 protein expression in early-passage HAEC treated with TEN or FTC+TEN
(Fig. 3.3B). However, p21 protein expression was increased in late-passage cells treated
chronically with TEN and FTC+TEN chronic (Fig. 3.3C). This result suggests that p53 is an
early responder in NRTI-induced senescence signaling.
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Figure 3.3. Chronic NRTI treatment augmented the accumulation of senescent cells and
increased p21 expression in HAEC. HAEC were treated with 10 μM of the indicated NRTI
for 10 passages. (A) Senescence-associated beta-galactosidase (SABG) was detected by x-gal
that senescent cells are depicted by a blue color. The number of blue stained cells in 1,000
cells is presented as % of senescent cells. The protein expression of p53 (B) and p21 (C) were
determined by immunoblotting and normalized to actin and GAPDH respectively. *p<0.05,
compared to early VEH; #p<0.05, compared to late VEH; n=3-4.
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3.3.3. Continuing NRTI treatment downregulated Parkin-mediated mitophagy in
HAEC
Mitophagy, the selective removal of mitochondria by autophagy, is an important
component of mitochondrial quality control. It can be categorized into two mechanisms based
on how damaged mitochondria are marked for elimination. One is mediated by receptors on
the mitochondrial outer membrane. An example of these receptors is Nix, a protein that can
become phosphorylated during mitophagic signaling so that it associates with the autophagic
machinery (Novak et al., 2010; Schweers et al., 2007). Another is ubiquitin-mediated
mitophagy, a process that is regulated by PINK1-Parkin signaling (Iguchi et al., 2013; D.
Narendra, Tanaka, Suen, & Youle, 2008). Here, we measured the protein expression of Nix,
Parkin, and LC3, and the colocalization of mitochondria with these protein markers to test
whether mitophagic activity is diminished after chronic NRTI treatment. Both Parkin and Nix
expression levels were significantly upregulated in all four groups of late passage compared
to early passage control cells (Figures 3.4A, B). However, in late-passage cells, chronic NRTI
treatment significantly reduced Parkin expression compared to the passage-equivalent control
cells (Fig. 3.4A). The colocalization of mitochondria and Parkin was also decreased for
chronic FTC and FTC plus TEN treatments (Fig. 3.5A). On the other hand, Nix expression
was upregulated in NRTI-treated early but not late passage cells (Fig. 3.4B). The
colocalization of mitochondria with Nix also exhibited no difference between groups (Fig.
3.5B). Finally, to measure autophagosome formation, we assessed the conversion of LC3-I
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to LC3-II, detected as two bands following SDS-PAGE. LC3 I is the cytosolic precursor.
LC3 II is conjugated with phosphotidylethanolamine and is present in autophagosome
(Kadowaki & Karim, 2009; Mizushima & Yoshimori, 2007). The LC3 II-to-LC3 I ratio, an
estimation of the activation step of autophagy formation, was slightly decreased after chronic
TEN treatment (Fig. 3.4C). Intriguingly, the colocalization of mitochondria and LC3 was
considerably upregulated in the chronic FTC plus TEN treatment group (Fig. 3.5C). The
above findings suggest that chronic NRTI may decrease the activity of ubiquitin-mediated
mitophagy.
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Figure 3.4. Mitophagy-mediating protein Parkin but not Nix expression was decreased after
chronic NRTI treatment. HAEC were treated with 10 μM of the indicated NRTI for 10
passages. Parkin (A) and Nix (B) protein expression levels, and LC3 II/LC3 I ratio (C) were
determined at early and late passages by immunoblotting. *p<0.05, compared to early VEH;
#p<0.05, compared to late VEH; n=3-4.
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Figure 3.5. Colocalization of mitochondria and Parkin was decreased in HAEC after chronic
FTC and FTC co-treatment with TEN. HAEC were treated with 10 μM of the indicated NRTI
for 10 passages. Mitochondria were stained with MitoTracker Deep Red (magenta) in late
passage HAEC. Parkin (A), Nix (B), or LC3 (C) were detected using primary antibodies and
were stained with FITC-conjugated (green) secondary antibodies. Mitochondria colocalized
with protein markers are depicted as the percentage of relative area in each cell. (D) Images
shown are representative of n=105 cells. *p<0.05, compared to VEH; results were compared
by using one-way ANOVA with Dunnett post-hoc.
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3.3.4. Elevated leak respiration after short-term NRTI treatment
To evaluate mitochondrial function in HAEC, we examined mitochondrial respiration
using high-resolution respirometry and measured ATP production. We noted a tendency
toward increasing respiration after continuous NRTI treatment in the early passage cells, and
there were significant increases in leak respiration in TEN and FTC+TEN treated cells (Fig.
3.6A). In the late passage cells, TEN and FTC+TEN treated HAEC exhibited a tendency
toward decreasing OXPHOS compared to passage-equivalent control cells (Fig. 3.6B).
However, ATP levels after chronic NRTI treatment was not altered. Instead, ATP levels were
decreased in all late passage treatment groups compared to early passage control cells (Fig.
3.6C). These results suggest that in endothelial cells, chronic NRTI treatment may induce
changes in OXPHOS that is not coupled to ATP production.
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Figure 3.6. Oxidative phosphorylation (OXPHOS) of HAEC after maintained in NRTI
chronically. HAEC were treated with 10 μM of the designated NRTI for 10 passages. (A, B)
Routine respiration was recorded in intact HAEC before adding substrates. Leak respiration
(PML) was recorded after adding pyruvate (P, 5 mM), malate (M, 2 mM), and digitonin (7.510 μg/106 cells) in the absence of ADP; N-linked OXPHOS (PMP, PMCytC, PMGP) was
recorded after adding ADP (P, 2.5 mM), cytochrome c (CytC, 10-20 μM), and glutamate (G, 10
mM); NS-linked OXPHOS (PMGSP) was recorded after adding succinate (S, 10 mM) in
permeabilized HAEC. *p<0.05, compared to early VEH at each respiratory state; n=11-12.
(C) ATP levels were determined by luminescence intensity and presented as percent change
relative to early VEH. *p<0.001, compared to early VEH; n=3. Abbreviations: N-linked,
ubiquinone oxidoreductase (NADH)-linked; S-linked, succinate dehydrogenase-linked.
3.3.5. Chronic NRTI treatment diminished vasoreactivity and nitric oxide production in
vivo
To further evaluate the cardiovascular impact of using NRTI chronically in a systemic
disease model, we treated Tg26 mice chronically with NRTIs. Though the Tg26 model is
non-infectious, chronic expression of the HIV viral proteins likely promotes a stress response
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similar to that occurring for cART-controlled HIV patients. To mimic the median age of our
current American population of HIV patients, we administered NRTI in the drinking water of
Tg26 mice and their littermate wild-type (WT) controls starting from 8 to 10 months of age.
Endothelium-dependent vasorelaxation was induced using increasing doses of Ach induced
after phenylephrine-induced vasoconstriction (Fig. 3.7A, B). The maximum level of
relaxation was reduced in all NRTI-treated Tg26 mice, but in only the TDF-treated WT mice
(Fig. 3.7C). Nitrite levels assessed in the plasma were decreased in Tg26 mice treated with
FTC or FTC+TDF, and in WT mice treated with TDF (Fig. 3.7D). These findings suggest that
the endothelial dysfunction caused by NRTI is independent of the influence of viral proteins,
but the viral proteins may sensitize the endothelium to NRTI toxicity.

Figure 3.7. Chronic NRTI treatment diminished vasoreactivity and nitric oxide production in
vivo. HIV-1 transgenic mice (Tg26) and the littermate wide-type (WT) mice were treated
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with FTC (40 mg/kg) and/or TDF (50 mg/kg) for 3 months in drinking water. (A, B) Ex vivo
vasoconstriction of mouse thoracic aortic ring was induced with phenylephrine, followed by
does-dependent relaxation to acetylcholine (ACH). (C) Maximal relaxation was determined
by non-linear regression. (D) Nitric oxide in mouse plasma was preserved as nitrite and
measured by chemiluminescent method. *p<0.05, compared to WT VEH; #p<0.05, compared
to Tg26 VEH; n=4-11.

3.3.6. FTC and TDF co-treatment decreased OXPHOS in EDL muscle in Tg26
Vascular endothelial cells are glycolytic in nature, relying heavily on glycolysis for most
of their energy demand, and mitochondria predominately serve as signaling organelles
(Quintero, Colombo, Godfrey, & Moncada, 2006). Mitochondria are much more plentiful in
skeletal muscles, where cells exhibit a high ATP demand due to the metabolic requirements of
repeated contractile activities. Since we could not reasonably isolate sufficient endothelial
cells for examining their mitochondrial function in vivo, we turned to skeletal muscle tissues
to estimate the chronic effect of NRTIs on mitochondrial respiration. In contrast to our in
vitro studies conducted using HAEC, all NRTI treatments produced a tendency toward
decreasing respiration in the EDL, a glycolytic type of muscle, extracted from both WT and
Tg26 mice (Fig. 3.8). The OXPHOS capacity of the EDL was significantly reduced in FTC
plus TDF treated Tg26, whereas the ETC capacity was decreased in both the TDF and the
FTC plus TDF treated T26 mice. Our result is supportive of the clinical finding that
myopathy is one of the common manifestations observed in PLWH who receive cART
(Dalakas et al., 1990).
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Figure 3.8. Chronic FTC and TDF co-treatment decreased OXPHOS in extensor digitorum
longus (EDL) muscle in Tg26. The leak respiration (PML) was measured after adding
pyruvate (5 mM) and malate (2 mM) in the absence of ADP; N-linked OXPHOS was
recorded after adding ADP (5 mM), cytochrome c (20 μM), and glutamate (10 mM); NSlinked OXPHOS (PMGSP) was recorded after adding succinate (10 mM); ETC capacity
(PMGSE) was recorded after titrating in uncoupler, CCCP, in saponin permeabilized WT (A)
and Tg26 (B) mouse muscle fiber. *p<0.05, compared to VEH at each respiratory state; n=610.
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3.4. Discussion
The first NRTI, AZT, was approved and available to treat HIV infection in the 1980s,
with several NRTIs released in the following two decades. Though HIV transmission and its
mortality are steadily getting under control, chronic conditions associated with prolonged
HIV infection and cART toxicities have become an important concern in the clinical
management of aging PLWH. CVD is one of the most frequent causes of death among HIV
patients undergoing cART (Feinstein et al., 2016; Rodger et al., 2013). The fixed-dose coformulation of FTC and TDF have been widely used as a backbone in cART since 2004
(AIDSinfo, 2019; Pozniak et al., 2006). FTC and TDF have no overlapping resistance
profiles and display an extensive sensitivity against HIV replication (Harrigan, Miller,
McKenna, Brumme, & Larder, 2002; Margot, Waters, & Miller, 2006). Both drugs undergo
modest levels of metabolism and are excreted via the renal system. Though they have no
expected pharmacokinetic drug-drug interactions in the liver, drugs interactions potentially
occur at the site of tubular secretion in the kidneys (Antoniou, Park-Wyllie, & Tseng, 2003;
Bang & Scott, 2003).
In our previous studies, we found that acute NRTIs induce endothelial dysfunction but
not apoptosis, and herein, we report that chronic FTC and TDF treatments promote
endothelial cell senescence. In fibroblasts, astrocytes, and HUVEC, excessive ROS
production and mitochondrial dysfunction were associated with NRTI-induced premature
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senescence, but the mechanism is not yet fully understood (Caron et al., 2008; Cohen,
D'Agostino, Tuzer, & Torres, 2018; Cohen, D'Agostino, Wilson, Tuzer, & Torres, 2017).
Several studies reported that NRTIs, such as AZT, TEN, and abacavir, inhibit telomerase
activity and shorten telomere length in immortalized cell lines and PBMC (Hukezalie,
Thumati, Cote, & Wong, 2012; Leeansyah et al., 2013; Strahl & Blackburn, 1996). Thus,
NRTI-mediated inhibition of telomerase activity was proposed as the underlying mechanism
of premature aging in HIV patients. We examined the role that mitochondrial function plays
in NRTI-induced premature endothelial senescence; however, whether mitochondrial
dysfunction is the cause of premature senescence or the consequence of cell aging still needs
to be delineated in future studies.
The endothelium is the main regulator of vascular homeostasis, modulating vascular
tone, inflammatory response and blood fluidity. Based on their secretory profile, senescent
endothelial cells reportedly exhibit a pro-inflammatory phenotype (Liu et al., 2012).
Additionally, both eNOS activity and NO production are decreased in senescent endothelial
cells, and the excess ROS produced in senescent cells should further decrease their NO
bioavailability, supporting their pro-inflammatory state (Matsushita et al., 2001). However,
prior reports have also demonstrated that under some conditions, senescent endothelial cells
adopt an anti-inflammatory phenotype with low VCAM-1 expression, suggesting that
senescent endothelial cells display a mosaic of inflammatory phenotypes (Coleman et al.,
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2013). Here, we found the over-production and accumulation of ROS and senescent cells,
respectively, in late-passage HAEC treated with NRTI. In addition, VCAM-1 was elevated in
late-passage HAEC treated with FTC plus TEN but not FTC or TEN alone. This result
suggests that chronic NRTI may induce differing inflammatory phenotypes in senescing
HAEC. Previously, AZT was reported to impair endothelium-dependent relaxation by
increasing superoxide levels (Sutliff et al., 2002). We also observed an impaired
vasorelaxation in FTC, TDF, and FTC+TDF treated Tg26, as well as in TDF-treated WT
mice. Our finding of more pronounced NRTI-induced effects in the Tg26 mice may suggest
that the systemically circulating viral proteins exacerbate endothelial cell sensitivity to
NRTIs. HIV viral proteins, such as gp120 (HIV envelop surface glycoprotein), trans-activator
of transcription (Tat) protein, and negative factor (Nef), cause endothelial dysfunction and
underly the mechanism of HIV-associated CVD (J. Jiang et al., 2010; Paladugu et al., 2003;
Wang et al., 2014). In addition, HIV gp120 and Tat promote endothelial senescence and
dysregulate senescence-associated microRNA 34a expression (Hijmans et al., 2018). There
are seven HIV viral proteins under the viral long terminal repeat (LTR) promoter expressed in
the Tg26 mouse line that includes gp120, Tat, and Nef (Dickie et al., 1991; Lu et al., 2006).
There is no CD4+ T cell depletion in heterozygous Tg26 mouse; therefore, the observed
endothelial dysfunction or senescence may not be immune stress induced. However, by some
mechanism, one or more of these proteins may sensitive the mitochondria to NRTI-induced
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toxicities, though, as yet, there are no prior reports that one or more of the proteins induces
mitochondrial dysfunction. Moreover, we did not observe endothelial dysfunction in mice
expressing these proteins – i.e., no reduction in vasodilation in the Tg26 mice compared to
their wildtype littermates.
In the current study, we observed that ROS and senescence markers were accumulated
along with mtDNA depletion after chronic NRTI treatment. However, the fluctuation in
mtDNA copy number - i.e., NRTI-mediated increase in passage 1 but decrease at higher
passages - aroused our curiosity about the response of mtDNA to ROS stimuli. Reduced
mtDNA integrity and mitochondrial function are known drivers for promoting vascular aging,
and storing mtDNA was proposed to delay this process (Foote et al., 2018). mtDNA is a
circular double stranded DNA that exists in multiple copies in mitochondria. Because of its
proximity to ROS in mitochondria and its lack of an efficient repair mechanism, mtDNA is
susceptible to oxidative damage. However, indirect mechanisms of compensating for mtDNA
are in place. For example, oxidative stress-induced mtDNA degradation was proposed as a
protective mechanism to prevent mutagenic mtDNA accumulation (Shokolenko,
Venediktova, Bochkareva, Wilson, & Alexeyev, 2009). Additionally, ROS was reported to
increase mtDNA copy number by triggering recombination-mediated replication (Hori,
Yoshida, Shibata, & Ling, 2009). Our findings may thus suggest a dynamic change in
mtDNA copy number in response to an oxidative NRTI challenge, wherein, mtDNA copy
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number is initially increased in response to ROS, but with chronic treatment, the cells’
capacity to restore mtDNA copy number is overwhelmed.
Mitochondrial dysfunction is an established hallmark of aging, and it is known that
senescent cells accumulate dysfunctional mitochondria (Lopez-Otin, Blasco, Partridge,
Serrano, & Kroemer, 2013). Endothelial senescence is associated with a disturbed
mitochondrial homeostasis, including a compromised biogenesis and mitophagic activity, or
dysregulation of fission and fusion dynamics. In a diabetic mouse model, redox regulation of
Drp1, a mitochondrial fission mediator, was shown to attenuate mitochondrial fission and
limit endothelial senescence (Kim et al., 2018). Mitophagy, or mitochondria-specific
autophagy, is a mitochondrial quality control mechanism that eradicates damaged
mitochondria in a mitochondrial fission-dependent manner (Frank et al., 2012). PINK1Parkin-mediated, also known as ubiquitin-mediated mitophagy, reportedly protects
endothelial cells from metabolic stress-induced damage (Wu et al., 2015). PINK1 is
constitutively imported into mitochondria and degraded by a protease. When mitochondria
are depolarized, PINK1 is stabilized on the outer mitochondrial membrane (OMM),
undergoes autoactivation, and then phosphorylates and recruits Parkin to mitochondria (Jin et
al., 2010; D. P. Narendra et al., 2010). Parkin is a cytosolic E3 ubiquitin kinase that is
selectively translocated to dysfunctional mitochondria and initiates poly-ubiquitination of
OMM proteins (D. Narendra et al., 2008). Cytosolic p53 inhibits Parkin translocation, thus
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impeding Parkin-mediated mitophagy and promoting mitochondrial dysfunction (Hoshino et
al., 2013). We found that in the late passage cells, NRTIs decrease Parkin protein expression
and its colocalization with mitochondria. This result suggests the downregulation of Parkinmediated mitophagy in NRTI-treated cells, and the early expression of p53 after NRTI
treatment may participate in decreasing Parkin translocation and mitophagic function. On the
other hand, in early passage cells, Nix expression was increased in TEN and FTC+TEN
treated HAEC, and in late passage cells, Nix levels were upregulated compared to early
passage. In other reports, Nix over-expression and restoration of mitophagy levels was shown
to maintain mitochondrial turnover in Parkin-deficient neurons obtained from a Parkinson’s
disease asymptomatic carrier (Koentjoro, Park, & Sue, 2017). We thus assume that in
senescent HAEC treated with NRTI, Nix upregulation serves to rescue the NRTI-mediated
reduction in Parkin-mediated mitophagy. However, the mechanism by which the NRTIs
inhibit Parkin activation is as yet unidentified.
Endothelial cells do not rely on mitochondrial respiration for their primary energy
supply and at most only 18% of their total cell volume is occupied by mitochondria. In
comparison, cardiomyocytes have about 32% (Tang, Luo, Chen, & Liu, 2014). Glycolysis is
responsible for ~85% of the total cellular ATP yield in vascular endothelial cells (De Bock et
al., 2013). Being highly glycolytic is physiologically advantageous, in that it minimizes
oxygen consumption and spares oxygen levels for transfer to surrounding tissues, thus
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reducing ROS generation. Nevertheless, mitochondria are a major source of endothelial ROS
and are important in redox signaling, where they regulate stress response pathways,
inflammation and atherogenesis (Pamukcu, Lip, & Shantsila, 2011). Therefore, an alteration
in the rate of mitochondrial respiration in endothelial cells may have a profound impact on
disease progression. In senescent cells, mitochondrial mass is increased and consequently
results in a higher oxygen consumption rate per cell (Mookerjee & Brand, 2015). In our
study, after chronic NRTI treatment, there was an increase in leak respiration in early passage
cells. Proton leak and mtROS generation are mutually modulated reportedly regulate
endothelial cell activation and inflammation (Nanayakkara, Wang, & Yang, 2019). In
endothelial cells, a reduction in cellular ATP production reportedly occurs during senescence
(Unterluggauer et al., 2008). Also, the expression of p53 limits their glycolytic activity by
blocking glucose uptake or inactivating enzymes within metabolic pathways (Kondoh et al.,
2005; Schwartzenberg-Bar-Yoseph, Armoni, & Karnieli, 2004). In accordance with these
prior reports, we observed an overall decrease in ATP levels in late-passage HAEC. Thus, the
changes in OXPHOS likely does not alter ATP production, presumably because the
mitochondrial volume in endothelial cells is minor.
Since it is nearly impossible to isolate endothelial mitochondria from mice for the
purpose of examining their function in vivo, we used skeletal muscle tissues to examine NRTI
mitochondrial toxicity and indirectly evaluate vascular function. Clinical studies indicate that
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systemic vascular function is associated with lower-limb muscular power in the elderly
(Heffernan et al., 2012). In addition, endothelial dysfunction and impaired regulation of
vascular tone would subsequently increase peripheral vascular resistance, leading to
insufficient oxygen supply to the skeletal muscle (Nyberg, Gliemann, & Hellsten, 2015;
Nyberg, Mortensen, Thaning, Saltin, & Hellsten, 2010). Muscle tissues are highly oxidative,
therefore, the mitochondrial toxicity resulting from NRTI treatment is expected to
dramatically decrease their mitochondrial respiration. In our exploratory analysis using
mouse EDL, the OXPHOS and ETC capacities were significantly decreased in Tg26 after
TDF or FTC+TDF treatment, supporting the clinical finding of myopathy in cART receiving
PLWH. Cellular senescence usually occurs in mitotic cells to prevent uncontrolled cell
division. However, recent studies have shown evidence of a post-mitotic cellular senescence
that is considered a protective mechanism to avoid apoptosis in these terminallydifferentiated cells (Farr et al., 2016; Grune, Merker, Jung, Sitte, & Davies, 2005; Jurk et al.,
2012). To more closely model the glycolytic nature of endothelial cells, in future studies, we
may need to collect peripheral blood mononuclear cells pooled from multiple mice, so that
we may compare NRTI-induced senescence pathways in both glycolytic and oxidative cells.
In summary, we demonstrate that chronic treatment with the clinically important FTC
and TEN/TDF co-formulations induce premature senescence and disrupt mitochondrial
homeostasis. We observed a downregulation of Parkin-mediated mitophagy, suggesting
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NRTIs may interrupt Parkin-mediated signaling through either decreasing its translation or
increasing its degradation. We also found that NRTIs decrease mtDNA copy number. We
utilized Tg26 as a model for PLWH to investigate the impact of chronic NRTI toxicity in
vivo. We propose that viral proteins may sensitize endothelial cells to NRTI toxicity. Our
findings with respect to mitochondrial respirometry support that NRTIs induce mitochondrial
toxicity both in vitro and in vivo. A limitation of this study is that we were not able to identify
a suitable endothelial senescence marker in vivo that would be helpful in clinically
diagnosing NRTI-induced endothelial dysfunction. Such a marker could potentially be useful
for identifying mechanisms for modifying treatment strategies for PLWH. Nevertheless,
taken together, our findings suggest NRTI induce a mitochondrial imbalance, promote
endothelial cell senescence and diminish vascular function.
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CHAPTER 4
CONCLUDING REMARKS
4.1. Research Summary
The extensive use of cART is credited with substantially increasing life expectancy in
HIV patients. However, approximately 50% of diagnosed HIV patients in the United States
are aged 50 or older (CDC, 2016). Consequently, non-AIDS-related, age-associated chronic
conditions are prevalent and exhibit an early onset in PLWH (Serrano-Villar et al., 2016).
Thus, in current cART era, the clinical management of HIV infection now includes
monitoring for chronic diseases. Among all classes of antiretroviral drugs, NRTIs are the
most commonly used, and several FDA-approved co-formulations are available and
recommended for patients in differing age groups or with certain chronic conditions
(AIDSinfo, 2019). In the current study, we sought to investigate chronic NRTI-induced
mitochondrial impairment and premature senescence in endothelial cells. After chronically
exposing HAEC and Tg26 mice to NRTIs, we utilized cellular and molecular biology
methods to examine mitochondria in vitro and vascular function in vivo. The major findings
are outlined in the sections that follow.
4.1.1. Chronic NRTI treatment causes premature endothelial senescence
In chapter 2, we utilized AZT, a thymidine analogue, 3TC, a cytidine analogue, and
TEN, an acyclic nucleotide analogue of adenosine, as representatives of the different
subclasses of NRTI. All three NRTIs resulted in a decreased population doubling and
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increased SABG accumulation, indicating an accelerated rate of senescence compared to
passage-equivalent controls (Figure 2.1-2.3). In particular, AZT-treated cells exhibited a
higher suppression of cell replication and more accumulation of SABG than 3TC- or TENtreated cells. Although AZT effectively inhibits retroviral replication and is still available for
antiretroviral therapy, less toxic NRTIs, such as FTC and TEN/TDF, are now the first-line
treatment for HIV patients. In chapter 3, we investigated the most common fixed-dose coformulation, FTC and TEN/TDF, in promoting senescence. FTC-TEN co-treatment increased
the accumulation of SABG and the senescence markers p53 and p21, and p53 was an early
responder in NRTI-induced premature endothelial senescence (Figure 3.3).
4.1.2. The ROS scavenger coenzyme Q10 rescues NRTI-induced premature endothelial
senescence
The pronounced oxidative stress induced by NRTIs has long been considered to play a
causal role in NRTI-mediate mitochondrial damage. Chronic maintenance of HAEC in AZT,
3TC, or TEN, led to a rise in mtROS (Figure 2.4A); FTC and TEN co-treatment also
increased ROS production (Figure 3.1B). However, cotreatment with exogenous Q10 reduced
the excess ROS and reversed chronic NRTI-triggered premature senescence (Figure 2.4B).
4.1.3. NRTIs trigger varying responses in mitochondrial respiration
Using a Seahorse XF analyzer, we found that chronic AZT, 3TC, or TEN treatments
suppressed ATP-linked respiration in endothelial cells; in addition, TEN decreased basal and
maximal respiration rates (Figure 2.5). On the other hand, using high-resolution respirometry
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we found increased OXPHOS in FTC and FTC-TEN co-treated cells (Figure 3.6). It is hard
to compare these two results, owing to the use of differing methods and NRTI of differing
subclasses. However, a unifying finding is that mitochondrial respiration was altered in
response to NRTI treatment. These results suggest that there may not be a universal
mechanism for NRTI-induced mitochondrial toxicity.
4.1.4. Chronic NRTIs disrupt mitochondrial homeostasis in endothelial cells
Mitochondrial DNA copy number was decreased after chronic FTC, TEN, or FTC-TEN
treatments (Figure 3.2). Human mtDNA encodes 13 polypeptides that are subunits of
complex I, IV, V, and cytochrome b. Therefore, a lack of ability to maintain a constant
number of mtDNA copies may impair ETC function. In addition, decreasing mtDNA copy
number can serve as a cellular signal for initiating senescence. Parkin protein expression and
colocalization with mitochondria were decreased in FTC and FTC-TEN co-treated cells,
suggesting that Parkin-mediated mitophagy was compromised (Figure 3.4-3.5). Mitophagy is
a key component of mitochondrial quality control, and its impairment may suggest
imbalanced mitochondrial homeostasis that predisposes the cell to undergo premature cellular
senescence.
4.1.5. Chronic FTC-TDF co-formulation impairs mitochondrial function and
vasoreactivity in vivo
FTC-TDF co-treatment decreased the maximum level of vasorelaxation and the plasma
nitrite level in Tg26 mice (Figure 3.7) that suggest vascular endothelial impairment. The
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mitochondrial metabolism of the vascular endothelium is not comparable to muscle tissues,
though, we used EDL as a substitution to evaluate mitochondrial function after NRTI
treatment in vivo. The OXPHOS capacity and ETC capacity of the EDL, a glycolytic muscle,
were significantly reduced in FTC-TDF treated Tg26. (Figure 3.8) that indicate damaging
mitochondrial respiratory function.
4.2. Future Directions
A limitation of our study was the lack of a definitive link between our in vitro findings
of premature endothelial senescence and our in vivo findings of NRTI-induced endothelial
dysfunction. The availability of biomarkers for assessing endothelial senescence in vivo using
non-invasive techniques is critical for the clinical characterization of premature senescence as
a mechanism of toxicity or disease etiology. MicroRNAs (miRNA) are small non-coding
RNAs that suppress gene expression by targeting genes at the 3’UTR. Several miRNA, such
as miR-341, miR-146a, and miR-217, have been shown expressed at increased levels in
senescent endothelial cells (Ito, Yagi, & Yamakuchi, 2010; Menghini et al., 2009; Olivieri et
al., 2013). Circulating miRNAs were found to be extremely stable and tolerate boiling,
extreme pH, long-term storage at room temperature, and repeated freeze-thaw cycles
(Mitchell et al., 2008). Detecting circulating miRNA in plasma may serve as a method in
future studies probing for senescence biomarkers in animals or human patients subjected to
NRTI treatment.
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In this study, we did not measure mtDNA mutations that contribute to heteroplasmy, the
co-existence of wild type and mutant mitochondrial genome. The degree of heteroplasmy has
been proposed associated with a variety of clinical conditions. In a retrospective study in
HIV-infected children, mtDNA mutations were found accumulated in PBMC during
antiretroviral treatment, and there was a significant difference in heteroplasmy (Ouyang et al.,
2018). If in future studies we can determine heteroplasmy by combining two-overlappedfragment mitochondria genome DNA PCR amplification, mtDNA barcoding, and parallel
sequencing. Using these methods, we could potentially identify mitochondrial genome-wide
heteroplasmy and the degree of heteroplasmy, and apply sequence data derived from
bioinformatics tools for further mechanistic studies (Huang, 2011). Another pitfall of this
study is that NRTI may inhibit telomerase activity directly. ABC, 3TC, AZT, FTC, and
TEN/TDF have been shown to inhibit telomerase activity, leading to accelerated shortening
of telomere length in activated PBMC (Leeansyah et al., 2013). Hypothetically, NRTI
induced re-localization of telomerase from the nucleus to the mitochondria may be a cause of
telomere shortening in the nucleus, hastening the degree of senescence. Future studies should
be designed to investigate this hypothesis and the mechanism for its regulation.
In studies presented here, we utilized Tg26 HIV-transgenic compared to wildtype mice,
both of which are raised on a C57BL/6 background strain. C57BL/6 mice are reportedly the
most atherosclerosis-susceptible inbred mouse strain and develop small lesions when fed a
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high cholesterol diet (Paigen, Holmes, Mitchell, & Albee, 1987). However, these mice do not
develop vascular lesions as easily as humans do. Thus, to further investigate whether NRTIinduced endothelial dysfunction culminates in an accelerated rate of atherogenesis, ApoEdeficient mice can be used for this purpose. These mice develop all phases of atherosclerotic
lesions so it should be an appropriate model to examine the development and progression of
the vascular lesion (Nakashima, Plump, Raines, Breslow, & Ross, 1994). Although the ApoE
deficient mice are not an appropriate model for HIV infection, this mouse model can be used
to translate in vitro findings to actual NRTI-induced atherosclerotic progression and evaluate
the efficacy of adjunct medications for relieving NRTI toxicity. To test whether the soluble
viral factors expressed by HIV further exacerbate the impact of NRTIs, the Apo E-deficient
mice could be crossed with the Tg26 mice, but such studies would require significant
additional time and resources.
MitoQ is an orally active mitochondria-targeted antioxidant in clinical development, it
mimics the role of endogenous ubiquinone to prevent mitochondrial oxidative damage (James
et al., 2007; Tauskela, 2007). MitoQ has been used in ApoE deficient mice and exhibited
inhibition in the development of features of a metabolic syndrome that is associated with
excessive mitochondrial oxidative damage (Mercer et al., 2012). In future studies, we can
utilize the ApoE deficient mouse strain to investigate chronic NRTI in atherosclerosis
progression, and maybe initiate a collaboration to apply MitoQ to test the feasibility of using
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this potential new therapy as an adjunct treatment in HIV patients. Pyrroloquinoline quinone
(PQQ) is a redox cofactor that stimulates mitochondrial biogenesis through increased PGC1α mRNA and protein expression (Chowanadisai et al., 2010). It may be worth testing
whether applying PQQ in both in vitro and in vivo models could activate PGC-1α expression
and alleviate NRTI mitochondrial toxicity. In these cases, ApoE-deficient mice would be a
feasible model for assessing the progression of atherosclerotic lesions.
4.3. Conclusion
Though the mitochondrial content in endothelial cells is low, endothelial mitochondria
are important in modulating cell fate and signaling. In this study, we hypothesized that NRTIs
induce mitochondrial imbalance, mitochondrial genome instability, and thus promote
premature endothelial senescence. We demonstrated that mitochondria serve as key targets
intimately involved in NRTI-induced premature senescence in endothelial cells. In searching
the specific effect of NRTI to mitochondrial homeostasis, we found that chronic FTC and
TEN co-treatment downregulates Parkin-mediated mitophagy pathway. These findings may
help to explain the high incidence of atherosclerosis in HIV patients. However, while no
robust theory explains all NRTI-induced alternations in mitochondrial respiration, further
investigation is necessary to fully delineate individual drug effects on mitochondrial function.
The co-formulation of FTC and TDF has long been the first-line cART and is currently
the WHO-recommended preferred regimen for HIV post-exposure prophylaxis. Therefore,
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understanding the etiology of toxicity from its long-term administration may help in
illuminating potential adjunct therapies for reducing its negative impact on the vascular
endothelium. Here, we observed impaired vasorelaxation in HIV transgenic mouse thoracic
arteries after chronic FTC and TDF co-treatment. In addition, we demonstrated that Q10 can
diminish NRTI-induced mitochondrial ROS and reverse endothelial senescence in vitro.
Together with recently advanced in Q10 bioavailability (Lopez-Lluch, Del Pozo-Cruz,
Sanchez-Cuesta, Cortes-Rodriguez, & Navas, 2019), we may be able to examine NRTI and
Q10 or MitoQ co-treatment in vivo in the future.
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APPENDIX A. SPRINGER NATURE LICENSE TERMS AND
CONDITIONS
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APPENDIX B. SEPARATE-CHANNEL IMAGES OF
IMMUNOFLUORESCENCE STAINING

Figure B1. Immunofluorescence staining images of mitochondria and Parkin in separate
channels. HAEC were treated with 10 μM of the indicated NRTI for 10 passages.
Mitochondria were stained with MitoTracker Deep Red (MTDR). Parkin was detected using
primary antibodies and stained with FITC-conjugated secondary antibodies. Mitochondria
colocalized with Parkin is presented in merge images. Images shown are representative of
n=105 cells.
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Figure B2. Immunofluorescence staining images of mitochondria and Nix in separate
channels. HAEC were treated with 10 μM of the indicated NRTI for 10 passages.
Mitochondria were stained with MitoTracker Deep Red (MTDR). Nix was detected using
primary antibodies and stained with FITC-conjugated secondary antibodies. Mitochondria
colocalized with Nix is presented in merge images. Images shown are representative of
n=105 cells.
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Figure B3. Immunofluorescence staining images of mitochondria and LC3 in separate
channels. HAEC were treated with 10 μM of the indicated NRTI for 10 passages.
Mitochondria were stained with MitoTracker Deep Red (MTDR). LC3 was detected using
primary antibodies and stained with FITC-conjugated secondary antibodies. Mitochondria
colocalized with LC3 is presented in merge images. Images shown are representative of
n=105 cells.
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